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This project aimed to improve the stability of the novel oncolytic virus, Seneca Valley virus 
(SVV). This was with the overarching goal of determining the residues and mutations thereof 
within the viral capsid that are responsible for capsid stability, to inform the future production 
of SVV Virus-Like Particles (VLPs) for use as a drug delivery vector.  
The thermal stability of wild-type SVV-001 was first investigated to determine a baseline to 
which thermostable mutants could be compared, and to inform a regimen of heating and 
passage to derive thermostable mutants. During optimisation of these initial experiments, 
heating of a sample containing approximately 107 PFU/mL SVV-001 to 58.5 °C for 30 minutes 
produced a single viral plaque. Virus collected from this plaque was shown to be resistant to 
heating at 56 °C, an improvement on the wild-type, which was shown to lose approximately 
99% viral titre to heating at 53.5 °C for 30 minutes. This thermostable phenotype was also 
confirmed using Particle Stability Thermal Release Assays (PaSTRy). Attempts to select for 
increasingly thermostable virus were unsuccessful.  
Mutant virus was purified and the capsid-coding region of the genome sequenced. This 
revealed four mutations in the thermostable mutants. One of these mutations, A1776G, was 
predicted to have an effect on the maturation of capsid proteins, which was supported by initial 
results of SDS-PAGE gel analysis. The other three mutations were either synonymous 
mutations well-conserved in Senecavirus isolates, or outside of the capsid coding region of the 
genome, and so were of limited applicability to the production of VLPs. 
Thermostable virus was then optimised for cryo-electron microscopy to determine its structure, 
with a low-resolution structure derived as a proof-of-principle. 
Future studies are warranted to determine if the A1776G confers a thermostable phenotype to 
the wild-type virus, and in turn to the SVV VLP. The basis for this phenotype should also be 
investigated, as well as a means to introduce the desired drugs into the genomeless capsid. 
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1.1.1 Incidence, epidemiology & contributing factors 
Globally, cancer remains one the greatest causes of mortality in humans. In 2018, there was an 
estimated 18 million new cases of cancer worldwide, as well as 9.5 million deaths 
(International Agency for Research on Cancer, 2019). Among the most prevalent cancers 
worldwide are lung, breast, prostate and colorectal cancers,  which together are thought to 
make up approximately 6.5 million of these new cases and 3.3 million of the overall deaths 
(Bray et. al., 2018).  
 
The incidence of individual cancers and their mortality in a given population is informed by 
the complex intersection of biological and cultural factors. Lung cancer represents a fairly 
straightforward example, in that it is most often related to the recreational smoking of tobacco. 
Recent statistics indicate that as the rates of smoking decline, for instance in males in higher 
income countries, so too the incidence of lung cancer decreases (Torre et. al., 2015). As 10-
15% of lung cancer sufferers in the US have ever smoked, smoking is not the sole modality 
through which people place themselves at risk of lung cancer (Samet et. al., 2009). Air 
pollution, through occupation or environment, increases risk to populations with low rates of 
smoking, with Chinese women as an example (Torre et. al., 2015). Other risk factors also 
include second-hand smoke exposure, aspects of diet, and infections (Samet et. al., 2009).  
 
In most countries throughout the world, breast cancer is among the chief causes of death for 
women (Ghoncheh, Pournamdar & Salehiniya, 2016). Whereas the risk factors that underpin 
lung cancer are largely dictated by lifestyle, those which underpin breast cancer in women 
appear to be mostly biological, including advanced age, age at first pregnancy, early onset 
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menarche and later than average menopause (McPherson, Steel & Dixon, 2000). Note that this 
is not an exclusive rule, as alcohol, oral contraceptive and therapeutic hormone use have each 
been identified as risk factors (Barnard, Boeke & Tamimi, 2015).  
 
Prostate cancer in men can be thought of as being the equivalent of breast cancer in women. It 
is an interesting cancer, as 80% of men who live to age 80 are thought to develop the condition, 
but clinically the lifetime risk is 8% (Bostwick et. al., 2004). For this reason, the observation 
has been made that “most men die with prostate cancer, rather than from it” (Bostwick et. al., 
2004 p. 2372). Genetics seems to play a significant role in the development of prostate cancer. 
One Quebec-based study showed that the odds ratio (OR) of developing prostate cancer if one 
to four of a man’s first-degree relatives also has prostate cancer is 9 (Ghandirian et. al., 1991). 
Another study from Jamaica showed that the OR for developing prostate cancer is 2.1 if a 
single first degree relative also has, or had, prostate cancer (Glover et. al., 1998). 
 
Colorectal cancer is the third most common cancer in both men and women worldwide, 
differentially effecting Westernised societies such as North America, New Zealand, Australia 
and Europe (Haggar et. al., 2009). This may be explained in part by vices such as alcohol and 
tobacco use, which are both shown to be associated with early onset colorectal cancer (Zisman 
et. al., 2006). Inflammatory bowel disease (IBD) and genetic inheritance can also play a role 
in colorectal cancer (Haggar et. al., 2009).  
 
1.1.2 Contemporary cancer treatments 
Common treatments for cancer include mono- or combination therapy regimens of surgery, 
chemotherapy and/or radiation therapy. None of these interventions are without risk, and often 
carry side effects which can be severe. In surgery, masses of cancer cells are physically 
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removed from the surrounding tissue, which by definition causes damage to this tissue. Taking 
the example of rectal cancer, results from multiple studies indicate that of those who receive 
surgery, 7% will develop a wound infection, 11% will suffer from anastomotic leakage 
(transfer of matter across the intestinal lumen into the body), and 12% will develop pelvic 
sepsis (Paun et. al., 2010).  
 
Chemotherapy encompasses a large range of therapies of different modalities. Chemotherapy 
drugs are most often introduced intravenously, exerting effects systemically, but preferentially 
against malignancies. This systemic toxicity manifests in negative side effects, for instance 
cisplatin, oxaliplatin, vincristine, methotrexate and cytarabine, among others, are known to 
cause central and/or peripheral nervous system complications (Verstappen et. al., 2003). 
Advances in understanding of cancers have brought about targeted chemotherapies, which 
include monoclonal antibodies and small molecule inhibitors. While generally considered less 
toxic, these too have side effects. These include the gastrointestinal perforation and 
haemorrhage that can be caused by bevacizumab, and the cardiac toxicity associated with 
lapatinib (Gerber, 2008).  
 
Radiation therapy utilises high-energy ionising radiation to cause DNA damage, and thereby 
cellular destruction, of healthy and tumour cells in the treatment field. The complications that 
can arise from therapeutic irradiation are well demonstrated in an oral context, where radiation 
therapy can cause mucositis (inflammation of oral mucosa), xerostomia (lack of saliva, altered 
properties of saliva), and osteoradionecrosis (tissue and bone degeneration) (Sciubba & 
Goldenberg, 2006).  
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In recognition of the toxicity, and sometimes lack of efficacy, of traditional cancer therapies, 
new strategies are being developed constantly. These include adoptive T-cell transfer (ACT) 
and the use of oncolytic viruses (OVs). ACT can be subdivided into three categories: tumour 
invading lymphocytes (TILs) transgenic T-cell receptor T-cells (TCR T-cells) and chimeric 
antigen receptor T-cells (CAR T-cells) (June et. al., 2018). TIL therapy is a personalised 
treatment strategy wherein invading tumour lymphocytes are extracted from excised patient 
tumours and co-incubated with tumour cells in the presence of IL-2. TILs which are shown to 
destroy tumour cells in vitro are then expanded and re-introduced to the patient to exert 
therapeutic effect (Rosenberg & Restifo, 2015). Transgenic TCR T-cell therapy makes use of 
T-cells transduced to express T-cell receptors specific to cancer antigen (Ping, Liu & Zhang, 
2018). An example of the cancer antigen targeted in TCR T-cell therapy is melanoma 
associated antigen recognised by T-cells-1 (MART-1). MART-1-recognising transgenic TCR 
T-cell therapy was able to produce objective responses in up to 30% of patients trialled in one 
study, but not without targeting of melanocytes in the skin, eyes and ears of patients (Johnson 
et. al., 2009). CARs are fusion proteins which contain an extracellular domain based on 
complementarity-determining region (CDR)-containing heavy and light chains of antibodies, 
and hinge domain, a transmembrane domain, and an intracellular signalling domain. CAR T-
cells have gone through multiple “generations” in their development based on the intracellular 
domains that can be incorporated. First generation CARs had the intracellular domain of CD3ζ, 
second had CD3ζ and either CD28 or 4-1BB, and third generation CARs have all three (June 
et. al., 2018). Second generation CAR T-cells have shown great efficacy against B-cell 
malignancies such as Chronic Lymphoid Leukaemia, at the cost of B-cell hyperplasia (Porter 
et. al., 2011). Figure 1 below surmises therapeutic strategies for the treatment of malignancies 
that are well established, such as surgery, chemotherapy and radiation therapy, as well as 




Figure 1: Contemporary treatments for cancers. A summary of the anti-tumour and off-
target effects of surgery, chemotherapy, radiation therapy, adoptive cell transfer therapy and 
oncolytic virotherapy. 
 
OVs will be discussed in greater detail in the coming text, but as the focus will be on those 




1.2.1 Picornaviral biology 
From the Latin “pico” meaning small, Picornaviridae are a family of small, non-enveloped, 
positive sense, single-stranded RNA viruses. The picornavirus family is well researched, with 
















































genomes of picornaviral species have a characteristic “L-4-3-4” format, where the single 
polyprotein is cleaved by virally encoded proteases into the Leader protein, which is not always 
present, and three polypeptide regions P1 (four structural proteins), P2 (three non-structural 
proteins) and P3 (four non-structural proteins), hence “L-4-3-4” (Bedard & Semler, 2004). At 
the 5’ extreme of picornaviral genomes is the 5’ untranslated region (UTR). The 5’ UTR 
associates with the viral genome associated protein (VPg) and contains important secondary 
structural features, such as the internal ribosome entry site (IRES). Ordinarily, an essential step 
in human cellular RNA translation is the 7-methyl guanosine cap interacting with the 
eukaryotic initiation factor (eIF) protein, this function in the cap-independent translation of 
picornaviral genomes however, is served by the IRES (Svitkin et al., 2001). Immediately 
following the IRES, the Leader protein is a protease that sits at the 5’ end of the translated 
picornaviral polyprotein. It should be noted that the Leader protein is not present in all species 
encompassed by the Picornaviridae family. The Leader protein is followed by the four capsid 
proteins, in what is denoted as the P1 region of the picornaviral polyprotein. From 5’ to 3’, the 
capsid proteins are VP4, VP2, VP3 and VP1 respectively. While VP1 and VP3 are cleaved 
from P1 proteolytically, VP4 and VP2 are usually processed from the precursor VP0 following 
genome packaging inside the viral capsid.  
 
The P2 region of the translated polyprotein consists of 2A, 2B and 2C. The picornaviral 2A 
protein is somewhat enigmatic, as it can be absent, present, or in some cases, be coded for twice 
in the genome. 2A proteins can be organised into five groups based on function and conserved 
residues, these are: chymotrypsin-like protease, parechovirus-like, hepatitis-A-like, 
apthovirus-like and cardiovirus 2A proteins (Yang et. al., 2017). The roles of 2B and 2BC are 
in the formation of pores in membranes of intracellular organelles, disturbing cation balances 
and impairing glycoprotein trafficking (Neiva et. al., 2003). 2C by itself has a range of activities 
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that can be specific to various viral taxa. In Seneca Valley virus (SVV) for example, 2C is 
shown to induce apoptosis (Liu et. al., 2019), whereas in Encephalomyocarditis Virus 
(EMCV), it has been shown to antagonise that IFN- (Li et. al., 2019). Most commonly, 
picornaviral 2C proteins are thought to associated with membranes and bind viral genomic 
RNA (Banerjee & Dasgupta, 2001).  
 
P3 consists of 3A, 3B, 3C and 3D. A sole function for 3A is not known, but it has been shown 
to interact with 3B, and the hydrophobic carboxy terminus of 3A is presumed to act as an 
anchor for 3AB in cellular membranes (Cameron, Suk Oh & Moustafa, 2010). 3B, which is 
also known as the viral genome associated protein (VPg) is a small protein which interacts with 
the 5’ terminus of the genome and plays an essential role in genome replication. 3B does this 
by providing a primer for RNA synthesis when uridylated by cis-acting replicative elements 
(CREs). The CREs are looped secondary structural elements which can occur at several places 
in the RNA genome, including 5’ and 3’ UTRs, and 2C regions. The protease encoded by 3C 
performs most cleavages of the picornaviral polyprotein as well as inhibiting host transcription. 
Last among the picornaviral proteins is 3D, the RNA-dependent RNA polymerase (RdRP) 
(Porter et.al., 1993). The 3CD protein has protease and CRE-binding activity, but does not have 
polymerase activity. Finally, the 3’ UTR of picornaviruses includes features such as the poly-
A tail, and occasionally a CRE (Cameron, Suk Oh & Moustafa, 2010).  
 
Figure 2 below describes the genome organisation and phylogenetic relationship between a 
number of picornaviral species. 
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Figure 2: Genomic relatedness of a select group of picornaviruses. A) Radial phylogenetic 
tree showing the relatedness of several picornaviral species grouped into the Aptho-, Seneca-, 
Cardio- and Enterovirus genera respectively. B) RNA sequences of picornaviral isolates were 
aligned using clustal omega (Sievers et. al., 2011). Abbreviations: TMEV Theiler’s murine 
encephalomyelitis virus MEV Mengovirus EMCV Encephalomyocarditis virus HRV Human 
Rhinovirus PV Poliovirus CVA Coxsackievirus A BEV bovine enterovirus EV71 enterovirus 
71 ECHO echovirus FMDV foot and mouth disease virus SVV Seneca Valley virus. 
 
1.2.2 Quasispecies: An RNA viral phenomenon 
The concept of quasispecies is crucial to understanding the evolutionary success of many RNA 
viruses, including picornaviruses. Rather than existing as clonal populations derived from a 
consensus nucleotide sequence, RNA viruses exist as mutant spectra, or mutant clouds as they 
can be termed (Domingo, Sheldon and Perales, 2012). Quasispecies therefore refers to the fact 
that individual virions within the same species can be sufficiently distinct so as to appear to be 
 19 
from separate species (Domingo, Sheldon and Perales, 2012). This is due in no small part to 
the activity of virally encoded RdRPs. The activity of RdRPs is inherently error-prone, with 
most thought to introduce an error rate of between 10-4 to 10-6 mutations per base-pair per 
round of replication (Stern et. al., 2014). The consequences of this error-rate for a hypothetical 
10,000 base-pair RNA virus is that for every genome duplication event, an average of one to 
0.01 mutations occur. The mutant spectra that are produced from this process are not reflective 
of a truly random process wherein bases at all positions are equally likely to be mutated, rather 
they are constrained by the functional consequence of each specific mutation by negative 
selection of unfit genomes (Domingo, Sheldon and Perales, 2012). Figure 3 below surmises 
the concept of RNA-viral quasispecies.  
 
Figure 3: Principle of adaptive advantage of the quasispecies phenomenon. The genomic 

















Taking the example of picornaviruses to expand on the idea of mutational constraints, the joint 
role of RNA secondary structures and the translated capsid proteins in forming functional 
virions means that the implications for mutations are two-fold. Firstly, there are several RNA 
secondary structures that need to be preserved for production of viral progeny, including 
IRESs, CREs, and as shown in the case foot and mouth disease virus (FMDV), packaging 
signals regularly interspersed throughout the genome (Logan et. al., 2018). Genomic RNA 
bound within picornaviral capsids has also been shown to be highly ordered, interacting with 
the interior aspects of capsid proteins (Shakeel et. al., 2016). Secondly, mutations are 
constrained by how they preserve the function of the translated viral proteins.  
 
1.3 Oncolytic Picornaviruses 
 
1.3.1 The field of oncolytic virotherapy 
The inception of oncolytic virotherapy was a product of the early 20th century, inspired by 
reports of patients with cancers such as leukaemia and Hodgkin’s disease surviving 
concomitant viral infections and showing evidence of clinical remission (Hoster, Zanes & Von 
Hamm, 1949, Pelner, Folwer & Nauts, 1958). These observations lead to a number of trials 
from the mid-to-late 20th century such as West Nile virus Egypt 101 against various cancers 
(Southam & Moore, 1952), Adenovirus versus cervical carcinomas (Georgiades et. al., 1959) 
and Mumps virus against various terminal cancers (Asada, T., 1974). Each of these trials 
showed varying degrees of protective effect. For instance, the trial concerning Adenovirus 
showed that 26 of 40 inoculations resulted in tumour necrosis (Georgiades et. al., 1959), and 
the Mumps virus trial resulted in complete regression of tumours in of 37 out of 90 trial 
subjects, as well as 42 instances of growth suppression (Asada, T., 1974). In 2015, an important 
milestone in the endeavour to make oncolytic virotherapy a viable therapy was reached. This 
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was the approval of the first oncolytic virus, modified herpes simplex virus-1 a.k.a. Talimogene 
Laherparepvec (T-VEC), by the US FDA for the treatment of malignant melanomas (Greig, S. 
L., 2016). Important to note is that T-VEC was not the first oncolytic virus to be approved 
worldwide, as Echovirus 7 (Rigvir) and modified adenovirus (Oncorine) have been approved 
in Latvia since 2004 (Alberts et. al., 2018) and China since 2005 respectively, (Xia et. al., 2004, 
Garber, K., 2006).  
 
1.3.2 Naturally occurring oncolytic picornaviruses 
There are species within the picornavirus family which, for a variety of reasons, have an innate 
selective toxicity against human cancers over healthy tissue. Figure 4 provides examples of 
picornaviruses shown in literature to have oncolytic activity, with little or minimal 
pathogenesis in humans. 
 
Figure 4: Naturally occurring oncolytic picornaviruses. A selection of picornaviral species 
whose oncolytic activity will be discussed, including coxsackievirus A21 (PDB accession 
number: 1Z7S) Seneca Valley virus (PDB accession number: 3CJI) echovirus 7 (PDB 




The discovery of coxsackievirus is accredited to Dalldorf and Sickles. In attempting to isolate 
Poliovirus from affected patients using unweaned “suckling” mice, the two observed an 
atypical paralysis of these mice due to skeletal muscle destruction, rather than the central 
nervous system damage as would be expected in Poliovirus infection (Dalldorf & Sickles, 
1948). The filtrable agent isolated from these mice could be inactivated in human sera and was 
shown to be distinct from other known viruses by host range (Dalldorf & Sickles, 1948). Since 
then the coxsackievirus species has broadened to include 29 serotypes, 23 in coxsackievirus A, 
which infect the skeletal muscle of mice, and 6 in coxsackievirus B, which infect a broader 
range of tissues (Bradley et. al., 2014). In humans, coxsackieviruses are considered “common-
cold viruses”, causing mild upper respiratory tract infections (Buckland, Bynoe & Tyrell, 
1965). Most coxsackieviruses use Intercellular Adhesion Molecule 1 (ICAM-1) as a primary 
receptor to facilitate viral infection of susceptible cells, with Decay Accelerating Factor (DAF) 
as a secondary receptor (Bradley et. al., 2014). Exceptions do exist however, such as 
coxsackievirus B3, which utilises coxsackievirus and adenovirus receptor (CAR) (Shafren et. 
al., 2004).  
 
The lion’s share of research into coxsackievirus as an oncolytic agent has gone into 
coxsackievirus A 21 (CVA21), registered as CAVATAK® by Viralytics Inc. (Bradley et. al., 
2014). CVA21 was investigated in vitro and in vivo in a range of cancers, including melanoma 
(Shafren et. al., 2004, Au et. al., 2005, Shafren et. al., 2014, Yuan et. al., 2015), multiple 
myeloma (Au et. al., 2007), breast cancer (Skelding et. al., 2009) and bladder cancer (Annels 
et. al., 2018). Highlights from these studies include that across these various cancers, ICAM-1 
and DAF expression were strong predictors of susceptibility to CVA21 infection, and that in 
animal models, CVA21 reliably suppressed (Au et. al., 2005, Skelding et. al., 2009, Shafren et. 
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al., 2014, Yuan et. al., 2015) or cleared (Shafren et. al., 2004, Annels et.al., 2018) introduced 
tumours. CVA21 was also shown to act in concert with other drugs such as immune checkpoint 
inhibitors (Shafren et. al., 2014, Yuan et. al., 2015) or viral-receptor upregulators (Annals et. 
al., 2018) to produce synergistic effects in eliminating in vivo tumours.  
 
Results from the previously mentioned experiments inspired Phase I - II clinical trials with 
CAVATAK® in melanoma (Shafren, Smithers & Formby, 2011, Andtbacka et. al., 2015, 
Andtbacka et. al., 2015), late-stage cancers (Pandha et. al., 2015, Pandha et. al., 2016, Pandha 
et. al., 2017) and bladder cancer (Pandha et. al., 2016). The findings of these clinical trials have 
been overwhelmingly positive, with CAVATAK® having been shown to be safe (Pandha et. 
al., 2017), as well as in some cases producing objective or complete responses (Shafren, 
Smithers & Formby, 2011, Pandha et. al., 2015, Pandha et. al., 2016). Clinical trials with 
CAVATAK® are still underway, with multiple clinical trials currently recruiting patients.  
 
Returning to the idea that CVA21 is a common cold virus, the transient and relatively mild 
infection brought about by this virus means that pre-existing immunity is common in humans 
(Au et. al., 2011). Pre-existing immunity of patients against CVA21 could mean that the virus 
is cleared before exerting therapeutic effects in a clinical setting. In anticipation of this 
phenomenon, a number of other less common coxsackievirus serotypes and strains have been 
investigated for a similar selective oncolytic activity to that of CVA21. For example, 
coxsackievirus A 13, A 15 and A 18 (CVA13, CVA15, CVA18) have each been tested as 
putative substitutions for CVA21, with CVA18 having the strongest selective activity against 
in vivo melanoma models, where all treated animals completely cleared tumours (Au et. al., 
2011). Importantly, no donated serum samples from melanoma patients or commercial IgG 
samples were shown to have neutralising antibodies against CVA13, CVA15 or CVA18, 
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whereas 20% of melanoma patients and both commercial IgG samples contained neutralising 
antibodies to CVA21 (Au et. al., 2011).  
 
Another trial pitted 28 enteroviral strains against 12 human cancer cell lines and a healthy bone 
marrow stroma control (Miyamoto et. al., 2012). From this trial CVB2 Ohio-1, CVB3 Nancy 
and CVB4 JBV emerged as promising candidates for oncolytic viruses, especially CVB3 
Nancy, which could clear a number of lung cancer tumours in vivo, though at the cost mild 
hepatic dysfunction and myocarditis (Miyamoto et. al., 2012). CVB3 Nancy, as well as other 
strains of CVB3 including 31-3-93, H3 and PD, were later tested for their activity against 
colorectal cancers (Hazini et. al., 2018). In this study it was CVB3 PD that stood out, having 
not only the greatest oncolytic activity, but also having the least toxicity to the murine hosts 
(Hazini et. al., 2018). CVB3 strain 2035 was also shown to have dose-dependent toxicity 
against endometrial cancers in animal models as well as ex vivo patient derived samples (Lin 
et. al., 2018). Lastly, three coxsackievirus B 6 live enterovirus vaccine (LEV) strains, LEV8, 
LEV14 and LEV15 were evaluated for toxicity against a panel of cancers of diverse origin 
(Svyatchenko et. al., 2017). LEV15 distinguished itself amongst the other strains by virtue of 
its selectivity for cancer cell lines. Importantly, LEV15 was shown to be able to bio-adapt to 
cell lines such as RD rhabdomyosarcoma cells and MCF-7 breast cancer cells, after repeat 
passage through these cells (Svyatchenko et. al., 2017). This observation, as well as that of the 
previously mentioned study wherein CVB3 PD was shown to have developed some adaptation 
to healthy cells, provides an interesting dual consideration (Hazini et. al., 2018). While it is 
encouraging that the host cell range of coxsackieviruses can be widened, thereby increasing 
the pool of patients that can potentially benefit from coxsackievirus virotherapy, this has to be 




Enteric cytopathic human orphan (Echo)-viruses belong to the enterovirus B species. Like 
coxsackieviruses, clinical focus has largely centred around one particular strain of Echovirus, 
Echovirus 7 (EV7), registered as Rigvir® (Alberts et. al., 2018). Rigvir® is named for Riga, 
Latvia, where the viromic monitoring of patients receiving the Salk inactivated Poliovirus 
vaccine lead to the discovery of EV7 (Donina et. al., 2015). In Latvia, it is thought that as many 
as 75% of cases of melanoma are treated with Rigvir®, its widespread use possibly influencing 
its approval in Georgia, Armenia and Uzbekistan (Alberts et. al., 2018). However, in countries 
with the most stringent requirements for experimentally proven drug safety and efficacy, such 
as many countries of the European Union, United States of America, and Japan, Rigvir® has 
yet to be approved (Babiker et. al., 2017). This is likely due to the unavailability of the results 
of clinical trials which are alluded in the literature to have occurred between 1965 and 1991 
(Alberts et. al., 2018).  
 
Most of the experimental data that are available is in the form of case studies and retrospective 
studies, with some in vitro work. Beginning with in vitro experiments, EV7 has shown 
cytotoxicity against melanoma, pancreatic adenocarcinoma, muscle rhabdomyosarcoma, 
mesenchymal stem cells, gastric carcinoma, lung carcinoma and human normal dermal 
fibroblasts (Tilgase et. al., 2018). To date, five case studies have been published in peer-
reviewed journals. These detail the improved outcomes of patients of a range of cancers and 
stages thereof after treatment with Rigvir®. One paper followed a stage IV melanoma patient, 
stage IIIA small-cell lung cancer patient and stage IV histiocytic sarcoma patient on a long-
term Rigvir® regimen (Alberts et. al., 2016). Each of the patients were given different drugs 
alongside Rigvir®, and so the role of Rigvir® in improving their condition is unclear, but in 
any case, all three had improved conditions and were stable at the time of publication, with no 
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parameters exceeding NCI CTCAE grade 1 (Alberts et. al., 2016). The other case studies 
followed patients for whom the prognosis was especially poor. Rigvir® along with FOLFOX-
4 and bevacizumab was used to treat a patient with a stage IV poorly-differentiated rectal 
adenocarcinoma, which carries a five-year predicted survival rate of 5% (Tilgase et. al., 2018). 
This drug cocktail caused sufficient suppression of metastases to allow further surgical 
resection of affected tissues, and further treatment post-surgery lead to complete response 
(Tilgase et. al., 2018). Finally, a case study in the treatment of a basal cell carcinoma (median 
expected survival 5 months) with Rigvir® as a monotherapy resulted in the patient being alive 
for 3.9 years up to the time up publication (Proboka et. al., 2018). 
 
The last bodies of work on Rigvir® are retrospective studies. The results of one indicated a 
statistically significant increase in 3-year survival time of melanoma patients receiving 
Rigvir® when compared to patients from a historical cohort who had opted for surgery alone 
or surgery in combination with other immunomodulators (Donina et. al., 2015). This study also 
suggested that direct, intratumoural injection of Rigvir® was more efficacious than 
intramuscular infusion, an effect which may be in part explained by another finding that 
administering Rigvir® locally increases the total proportion of active (CD38+) and cytotoxic 
(CD8+) T-cells present (Bruvere et. al., 2002). Another retrospective trial enrolled stage IB 
through to stage IIC melanoma patients, with 52 patients enrolled for Rigvir therapy and 27 in a 
control group. The Rigvir® group in this case had a lower mortality rate, but the time spent 
disease-free was unchanged between the two (Donina et. al., 2015). 
 
1.3.2.3 Bovine Enteroviruses 
The International Committee for the Taxonomy of Viruses (ICTV) regularly releases reports 
on the official nomenclature of viruses. It does so in an attempt to create a cohesive system 
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through which the disparate and varied virology research around the world can be produced 
and evaluated by virologists universally. As a consequence of this, viruses often have their 
names changed and are retroactively moved between species etc. While currently bovine 
enterovirus 1 (BEV1) & bovine enterovirus 2 (BEV2) are now categorised as enterovirus E & 
enterovirus F respectively (Adams et. al., 2013), much of the research into their oncolytic 
activity occurred before this distinction made, and so it becomes convenient to discuss them 
together. 
 
Bovine enteroviruses do not cause disease in humans, but as their name suggests they are 
endemic pathogens of cows (Smythe et. al., 2002). The cytotoxicity of BEV1 against human 
cancer cell lines was first tested in 1971, when 65% of cancer cell lines tested met the threshold 
for significant viral killing by BEV1, compared to 4% of healthy cell lines (Taylor et. al., 1971). 
Of those cancer cell lines that were susceptible to BEV1 mediated killing, the degree of 
susceptibility varied widely, between 18% cell death in Ehrlich ascites and 98% cell death in 
L-cells (Taylor et. al., 1971). The variability of BEV1 cytotoxicity against these cell lines was 
thought to be receptor based, as cellular treatment with Vibrio cholerae neuraminidase (VCN) 
showed a dose and time dependent inverse correlation between VCN exposure and viral titre 
following BEV 261 infection in a panel of susceptible cancer cells (Stoner et. al., 1973).  
 
Referring briefly back to coxsackievirus, CVB3 (Svyatchenko et. al., 2017) and CVB6 (Hazini 
et. al., 2018) were shown to be able to adapt to various cell lines through repeated passage, 
however, the same could not be achieved with BEV1 (Taylor et. al., 1971). The same study 
also showed that BEV1 could clear sarcoma-1 xenografts and suppress leukemia 4946 tumours 
in mice (Taylor et. al., 1971).  
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Somewhat atypically, in addition to the studies in mice, BEV1 has been tested in rabbits and 
dogs with cancer, which both tolerated BEV1 well (Hodes et. al., 1973). Of note: BEV1 treated 
mice were shown to suppress ascites sarcoma 180 tumours, and a BEV1 treated dog had a 
transient positive response to its seminoma (Hodes et. al., 1973). In the most recent study of 
oncolytic bovine enterovirus in vivo, rabbits with induced adult T-cell-like leukemia showed 
increased survival when given BEV MZ-468, with treatment animals surviving up to four 
months until the end of the trial, whereas control animals died by day 11 (Shingu et. al., 1991). 
 
1.3.2.4 Encephalomyocarditis Virus 
Encephalomyocarditis virus (EMCV) was discovered in 1945 as a result of a captive male 
gibbon suddenly and inexplicably dying of pulmonary oedema and myocarditis (Helwig & 
Schmidt, 1945). Mice treated with the filtered fluid from this oedema developed paralysis and 
myocarditis (Carocci & Kassimi, 2012). 
 
Columbia-SK virus, the name by which EMCV was known in 1965, was shown experimentally 
to exert therapeutic effects on fructose sarcomas in mice and rats, especially in rats (Kuwata 
et. al., 1965). While research into EMCV continued, research into its oncolytic properties 
underwent a 50-year hiatus before EMCV was shown to have significant selective toxicity 
against retinoblastomas (Adachi et. al., 2006) and clear-cell renal cell carcinomas (Roos et. al., 
2010) in vivo.  
 
1.3.3 Engineered oncolytic picornaviruses 
While some picornaviruses have an innate selective toxicity for human cancers, there also exist 
picornaviruses specifically engineered for the purpose of oncolytic virotherapy. There are a 
number of reasons why these viruses may be altered, including attenuation of pathogenesis and 
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to increase immune evasion. Figure 5 contains examples of engineered picornaviral species, as 
well as the changes implemented for oncolytic virotherapy, which will be discussed in greater 
detail.  
 
Figure 5: Engineered oncolytic picornaviruses. Poliovirus (PDB accession number: 1HXS) 
has been altered in a number of ways for oncolytic virotherapy, among them is the replacement 
of the wild-type IRES of the sabin strain of poliovirus 1 with that of human rhinovirus 2 to 
construct PVSRIPO. Theiler’s murine encephalomyelitis virus (PDB accession number: 
1TME) can be engineered to express tumour antigen in the leader protein, with chicken 
ovalbumin commonly used as a proof-of-principle. Oncolytic mengovirus (PDB accession 
number: 2MEV) attenuated by the introduction of sequences complementary to micro-RNAs 
upregulated in healthy tissue. 
 
1.3.3.1 Poliovirus 
Poliovirus (PV) is best known as the causative agent of poliomyelitis, a disease which causes 
extensive paralysis in 1-2% of those people infected (Mehndiratta, Mehndiratta & Pande, 
2014). The basis for PV causing poliomyelitis in humans is the gastric and neuronal cell 
expression of CD155, also known as Necl5 (nectin-like molecule 5) or PVR (Poliovirus receptor) 
(Strauss et. al., 2015). As wild-type poliovirus carries the inherent risk of poliomyelitis, the 
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investigation into poliovirus as a cancer therapeutic has been with the express goal of 
ameliorating neurotoxicity while retaining oncolytic activity. Among the engineered 
polioviruses investigated for their use in oncolytic virotherapy are live attenuated poliovirus 
(LAPV), poliovirus replicons, A133Gmono-cre PV and perhaps most importantly PVSRIPO. 
 
LAPV, which is the attenuated Sabin strain of poliovirus 1 (PV1), was shown to have 
infectivity in bone and soft tissue cancer cell lines in vitro, as well as being able to significantly 
decrease sarcoma xenograft tumours in vivo (Atsumi et. al., 2012).   
 
Another method to attenuate PV neurotoxicity is by using replication incompetent poliovirus 1 
(PV1) replicons. Encapsidated replicons with the P1 segment of the PV1 genome deleted have 
been produced by co-infection of helper cells with a complementing P1-encoding Vaccinia virus 
vector (Ansardi et. al., 2001). Once inside the targeted cell, the PV1 replicon RNA genome is 
capable of replicating and causing cell lysis. However, the replicons cannot form full 
encapsidated virions to spread to other cells, as the lack of the P1 region prevents capsid 
formation. PV1 replicons have shown broad spectrum cytotoxicity against central nervous 
system and non-central nervous system tumours, and ex vivo primary patient tumours (Ansardi 
et. al., 2001). PV1 replicons significantly prolong survival of murine glioblastoma models by 
infecting primary tumours as well as distal metastases (Ansardi et. al., 2001). 
 
A133Gmono-cre PV is a PV mutant engineered specifically for oncolytic virotherapy (Toyoda 
et. al., 2007). The development of A133Gmono-CRE PV began with the observation that base 
substitutions in the 5’ UTR can attenuate wild-type PV. The issue with this however, was that 
these substitutions were never stable (Toyoda et. al., 2007). To decrease the chance of revertant 
mutants, researchers designed mono-CRE PV, which was wild type PV1 with the CRE moved 
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from the 2C protein to the 5’ UTR (Toyoda et. al., 2007). This both interrupted the 5’ UTR and 
prevented escape mutants due to essential function of the CRE. Mono-CRE PV strains 
developed a range of adaptations to infecting neuroblastoma cells in vivo and in vitro, though 
a single mutant, A133G, arose in both instances (Toyoda et. al., 2007). Going forward then, 
A133Gmono-cre PV was shown experimentally to have potent activity against neuroblastomas 
in vivo (Toyoda et. al., 2007). Both the CD8+ T-cells from A133Gmono-CRE treated mice and 
the non-infectious lysate from A133Gmono-CRE treated neuroblastoma cell cultures were later 
shown to effectively vaccinate mice from neuro-2a neuroblastoma cell challenge (Toyoda et. 
al., 2011). 
 
The greatest current prospect for the use of PV as a cancer therapy is PVSRIPO. PVSRIPO 
(sometimes referred to as “PV1(RIPOS)” in early literature) is the Sabin strain of PV1 (PVS) 
with IRES substituted with that of Human Rhinovirus 2 (HRV2) (Gromeier, Alexander & 
Wimmer, 1996, Jahan, Wimmer & Mueller, 2011). This attenuates PVSRIPO in neuronal cells 
(Jahan, Wimmer & Mueller, 2011, Cello et. al., 2008). There are a few reasons for this 
attenuation. For one, the HRV2 IRES is thought to have properties unsuited for the recruitment 
and activity of translation complexes specific to neurons (Brown & Gromeier, 2015). Another is 
the sequestration of double stranded RNA binding protein 76 (DRBP76) to the nuclear 
compartment of neoplastic cells, as opposed to its role in binding secondary structural elements 
of the HRV2 IRES in the cytoplasm of healthy cells (Brown & Gromeier, 2015). Cancer cells, 
generally speaking, have deregulated mitogenic signalling, and as such favour the m7G cap-
independent translation of viral genomes (Brown & Gromeier, 2015).  
 
PVSRIPO has demonstrated potent oncolytic activity in a breadth of cancers, including gliomas 
(Merrill et. al., 2004), breast cancers (Ochiai et. al., 2004, Holl et. al., 2016), glioblastoma 
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multiforme (Ochiai et. al., 2006), melanomas (Walton et. al., 2018), astrocytomas (Yang et. al., 
2009, Dobrikova et. al., 2008) and prostate cancers (Holl et. al., 2016).  
 
The oncolytic activity of PVSRIPO is in part due to its immunostimulatory properties. PVSRIPO 
causes sub-lethal infection in human macrophages, inducing expression of major 
histocompatibility complex class II (MHC II) and costimulatory molecules, leading to IFN-, 
IL-12 and TNF- production (Brown et. al., 2015). This immune stimulating effect could also 
be induced in human dendritic cells (DCs) after incubation with the virus-free lysate of PVSRIPO 
destroyed cells, stimulating tumour-antigen specific T-cells (Brown et. al., 2017). Similar to 
macrophages, activation of DCs occurs partially through sublethal infection producing low viral 
progeny, and is magnified in the presence of tumour lysate, as measured by CD40, CD80, IFN-
 and TNF- expression (Brown et. al., 2015). PVSRIPO oncolysis releases cancer antigens, 
including MART-1 (melanoma-associated antigen recognised by T-cells-1), DAMPs (damage-
associated molecular patterns, e.g., HSP 60/70/90, HMGB1 protein) and double-stranded RNA 
(dsRNA) (Brown et. al., 2017). In mice, mRIPO, which is PVSRIPO adapted to mouse 
astrocytoma cells, was used to treat OVA-expressing melanomas. Infection of these melanomas 
with mRIPO produced cytotoxic T-lymphocytes (CTLs) primed against OVA, as well as native 
melanoma antigen tyrosinase related protein 2. This delayed tumour growth, increased survival 
times and induced invasion of neutrophils, DCs and T-cells in to tumours (Brown et. al., 2017). 
 
As with any PV-based vaccine, PVSRIPO has been tested for pathogenesis in macaques, as per 
World Health Organisation (WHO) standards. Ex vivo cultures of macaque and human kidney 
cells displayed no appreciable infection after exposure to PVS or PVSRIPO (Dobrikova et. al., 
2012). In live macaques, PVSRIPO was patently safe, with all animals surviving to trial’s end. 
The tested macaques also did not shed virus in bodily fluids and only one had any measurable 
 33 
viral titre in the spinal cord and pons / medulla (Dobrikova et. al., 2012). PVSRIPO has been 
entered in to clinical trials. One Phase I clinical pitted PVSRIPO against a 13-strong cohort of 
patients with recurrent glioblastoma. Consistent with the trial in macaques, this trial 
demonstrated the safety of PVSRIPO, with no patients developing adverse NCI CTCAE 
(National Cancer Institute Common Terminology Criteria for Adverse Events) events grade 3 or 
above from PVSRIPO, though one experienced a grade 4 event from a catheter removal (Trotti 
et. al., 2003, Desjardins et. al., 2014). Another Phase I clinical trial of 61 glioblastoma patients 
focused on dose finding, indicating an optimal treatment dose of 5x107 TCID50 (Desjardins et. 
al., 2018). This trial also showed PVSRIPO had a protective effect on patient survival when 
compared to historical controls, with a 36-month survival rates of 21% and 4% respectively 
(Desjardins et. al., 2018). 
  
1.3.3.2 Theiler’s Murine Encephalomyelitis Virus 
The prospective use of Theiler’s murine encephalomyelitis virus (TMEV) for cancer therapy 
deviates from that of most other oncolytic viruses. This is because rather than direct infection 
and lysis of tumour cells, TMEV is more often engineered to express tumour antigen, thereby 
directing the host immune system to clear tumours as an extension of clearing TMEV.  
 
Most commonly in the literature, chicken ovalbumin (OVA) is introduced to the Leader protein 
of TMEV (TMEV-OVA) to generate a cytotoxic immune response against tumours also 
exogenously expressing OVA. While the addition of OVA comes at a cost to the virulence of 
TMEV (Pavelko et. al., 2011, Pavelko et. al., 2013), this alteration has indeed been shown in 
multiple studies to generate adaptive immunity to OVA (Bell et. al., 2014), leading to 
suppression of tumours and increased survival times in murine models (Renner et. al., 2015).  
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TMEV is known to harbour a highly immunogenic region in the VP2 capsid protein (VP2121-
130) and so any adaptive immune response generated against TMEV-OVA is in part against OVA, 
and in part against TMEV, including VP2121-130 (Bell et. al., 2014). As VP2121-130 specific 
immunity does not further the cause of tumour suppression, attempts have been made to 
emphasise OVA-specific immune responses over VP2121-130 specific immune responses. 
Deletion of the VP2121-130 region in TMEV-OVA was shown to increase the relative amount of 
Cytotoxic T-Lymphoctyes (CTL’s) targeted against OVA in vivo (Bell et. al., 2014). Vector 
silencing on the other hand, the exposure of the host to TMEV viral proteins before TMEV-OVA 
infection, seemed not to have any effect on the immune response directed toward OVA, tumour 
progression, or overall survival of mice with melanoma or glioma (Malo et. al., 2017).  
 
OVA is widely used as a model antigen for its high immunogenicity (Martner et. al., 2013), but 
authentic tumour antigen is often not as immunogenic. That being said, engineered TMEV 
vaccination does still work with weakly immunogenic tumour antigen, as shown by experiments 
with TMEV expressing p66 in a murine breast cancer model (Pavelko et. al., 2013).  
 
Not all of the research on TMEV in an oncolytic context has been as a cancer vaccine. While 
the DA strain of TMEV was ineffective in controlling breast cancers and melanomas in vivo, a 
chimeric fusion with the more neurovirulent strain GDVII was effective, significantly delaying 
B16 melanoma tumour outgrowth and increased survival when compared to DA strain and 
vehicle controls (Bell & Pavelko, 2016). This fusion took the 3’ end of the 5’ UTR to the 3’ end 
of the 2C protein of the DA strain and replaced it with that of the GDVII strain, the resultant 
chimeric virus named GD7-KS1 (Bell & Pavelko, 2016).   
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1.3.3.3 Mengovirus 
Mengovirus (MEV) was originally isolated from a Rhesus monkey which developed sudden 
paralysis. MEV is a novel virus in that it has a diverse range of mammalian hosts, including 
voles, squirrels, elephants, swine, wild boar, racoons, antelope, lions, birds and several 
species of non-human primate (Carocci & Kassimi, 2012).  
 
Due to the tenacity with which MEV infects a broad range of mammalian cell lines, research 
into its oncolytic activity has been undertaken with an attenuated version of MEV, vMC24, 
which is a poly-C truncated mutant (Dethlefs et. al., 1997). However, even this mutant caused 
paralysis in test mice, and so researchers utilised a novel strategy in engineering vMC24 to 
include complementary sequences to micro-RNA’s (miRNAs) preferentially expressed in 
healthy tissues infected by vMC24 (Ruiz et. al., 2016). A number of vMC24 variants were 
produced, with combinations of sequences complementary to miR125b (expressed in brain 
tissue), miR124 (expressed in neurons), miR133 and miR208a (enriched in cardiomyoctyes). 
Among these, a construct called vMC24-NC stood out as producing low viral titres in the brain, 
spine and heart of infected test mice (Ruiz et. al., 2016). Not only did vMC24-NC not cause 
negative side-effects, but it could also clear multiple myeloma tumours previously shown to be 
refractory to vMC24 infection in 40% of mice (Ruiz et. al., 2016). vMC24-NC contained two 
copies of complementary miR124 sequences in the 5’ UTR, and one of each of miR133b and 
miR208a in the 3’ UTR (Ruiz et. al., 2016). 
 
 
1.4 Seneca Valley Virus 
 
1.4.1 Introduction and discovery 
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Seneca Valley virus (SVV) is a member of the picornaviridae family as well as the first and 
namesake species of the senecavirus genus (Hales et. al., 2008.; Cartens, E. B., 2009; Adams 
et. al., 2015). A schematic representation of the SVV genome as well as the internal and 
external structures of the protomers, pentamers and capsids based on SVV crystal structure is 
shown in Figure 6 (Venkataraman et. al., 2008). 
 
The first strain of SVV to be discovered, SVV-001, was initially observed as a cell culture 
contaminant during development of a paired, replication-deficient adenovirus – helper cell 
gene therapy vector production system (Fallaux et. al., 1998). When this gene therapy vector 
production system, PER.C6 cells and E1 deleted adenovirus, was used again in 2002, cell 
cultures that succumbed to premature cytopathic effect (CPE) were investigated. Purification 
by ultracentrifugation followed by Sodium Dodecyl-Sulfate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) revealed three protein bands of 36, 31 and 27 kDa length. These 
most likely corresponded to SVV VP2, VP3 and VP1 respectively (Strauss et. al., 2018). N-
terminal sequencing of two of the protein bands revealed a close sequence relatedness to 
cardioviruses. Viral infection of PER.C6 cells was also confirmed with electron microscopy of 
cells inoculated with purified virus. SVV gets its name from Seneca Valley, Maryland, USA 
where Gene Therapy Inc., who performed this work, is located.  
 
SVA can be stratified into 3 clades based on temporal isolation. Clade I consists of the 
originally isolated strain SVV-001, Clade II is a grouping of historical SVV strains taken from 
samples isolated in the US from the 80’s and 90’s that were re-tested following discovery of 




Figure 6: Organisation of the SVV genome. Starting with the positive-sense, single stranded 
RNA genome in its full form, complete with genome associated protein (Vpg), descending 
through the translated polyprotein, its further division by viral proteases and finally maturation 
of structural proteins as a result of genome packaging (Hales et. al., 2008). Also shown are the 
crystal structures of the interior and exterior of the protomer, pentamer and viral capsid 
(Venkataraman et. al., 2008). Capsid structures generated with UCSF Chimera (Petterson et. 
al., 2004). 
 
1.4.2 A novel oncolytic picornavirus 
SVV is counted among the ranks of picornaviruses that display a natural selective tropism for 
human cancer cells (Morton et. al., 2010). 
 
Capsid Exterior Capsid Interior 
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In vitro studies of SVV indicated potent, selective activity against a range of cancer cell lines 
with a unifying feature of having neuroendocrine features. Figure 7 surmises two in vitro 
studies of SVV-001 (NTX-010) against panels of cancer and non-cancer cell lines. 
 
 
Figure 7: In-vitro cytotoxicity of SVV-001 for cancer cell lines of human origin. Human 
cancer cell lines were organised by the site of original isolation and stratified by IC50 
(proportion of SVV-001 versus target cell line required to cause death in 50% of those cells) 
according to pooled results from two studies (Reddy et. al., 2007.; Morton et. al., 2010). Those 
cell lines studied which showed no permissivity to SVV infection were omitted. 
 
These studies showed the very first signs of the potential for SVV to be used as a cancer 
therapeutic. One of the in vitro studies also showed that SVV-001 is not inactivated by human 
blood components, does not cause haemagglutination of human erythrocytes and that 
neutralising antibodies to SVV-001 have a very low prevalence among a random selection of 
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blood samples (Reddy et. al., 2007). The same study also showed that SVV-001 is well 
tolerated in murine models (Reddy et. al., 2007). 
 
Researchers then began to evaluate SVV efficacy in an in vivo setting. Attached to one of the 
aforementioned in vitro studies was a trial in which H446 (Small Cell Lung Cancer) and Y79 
(Retinoblastoma) cells were injected in to the flank of athymic mice. In both cases SVV-001 
was sufficient to completely destroy these tumours, and at the lower concentrations a reduction 
in tumour mass was shown in H446 (Reddy et. al., 2007). Another trial centred around the 
treatment of retinoblastomas in mouse xenograft models, as the previous trial showed success 
with the Y79 cell line, but did not address the ability for SVV to diffuse across the blood-brain 
barrier (BBB).  Traversing the BBB would be necessary if SVV-001 were ever to be used in a 
clinical setting for the treatment of retinoblastoma. SVV-001 was shown in this study to greatly 
reduce intraocular tumour burden and thus was able to cross the BBB (Wadhwa et. al., 2007). 
Though some residual tumours were observed to remain post-treatment, this was thought to be 
due to lack of tumour vasculature, which would not be the case in a human retinoblastoma 
(Wadhwa et. al., 2007).  
 
The ability for SVV-001 to cross the BBB brings into question other important cancers which 
are complicated by the necessity of drug permeability across the BBB. One such cancer is 
medulloblastoma, the most common form of paediatric brain cancer (Rood, MacDonald & 
Packer, 2004; Huse & Holland, 2010). An in vivo study of 10 primary medulloblastoma 
xenograft mice, 5/10 had significant tumour growth repression, while the other 5 did not (Yu 
et. al., 2010). Another important finding from this study was that a subpopulation of 
medulloblastoma Cancer Stem Cells (CSC’s), identified as being CD133+, are effectively 
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killed by SVV-001 (Yu et. al., 2010). This is important as CSC’s are thought to have increased 
resistance to radiation therapy (Hambardzumyan et. al., 2008).  
 
Based on encouraging results with medulloblastoma treatment, a similar trial involving 6 
glioma xenografts was undertaken. In vitro experiments showed among these clinical isolates, 
4 were permissive to SVV-001, while 2 were resistant, and this was consistent for both cell 
monolayers and neurospheres (Liu et. al., 2013). This trial also showed that intravenous SVV-
001 injection of 5x1012 viral particles per kg mouse body weight (vp/kg) had a significant effect 
in prolonging survival times in mice with medium (1-4 mm) and small (<1 mm) xenograft 
tumours from permissive cell lines, and interestingly also one of the resistant cell lines (Liu et. 
al., 2013).  
 
H446 Small-Cell Lung Cancer (SCLC) cells were shown to be particularly susceptible to SVV-
001 infection. To interrogate the activity of SVV against SCLC more broadly, tumour cells 
from three classic and three variant sub-type patient tumours were grown in vitro and 
transplanted into mice (Poirier et. al., 2013). In vitro and in vivo testing showed that the classic 
sub-type SCLC was completely resistant to SVV oncolysis, whereas the variant sub-type cells 
were highly susceptible (Poirier et. al., 2013). This lead to the hypothesis that susceptibility to 
SVV might be positively correlated to NEUROD1 expression, and negatively correlated with 
ASCL1 expression (Poirier et. al., 2013). 
 
SVV has entered a number of clinical trials. First, a phase I clinical trial of 30 patients with SCLC 
was undertaken (Rudin et. al., 2011). Patients treated with NTX-010 between 107 to 1011 vp/kg 
showed no dose limiting toxicities, with flu-like symptoms mainly manifesting in the lower dose 
cohorts. Neutralising antibodies were detected as early as two weeks into treatment. In terms of 
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outcomes, one patient showed disease stabilisation while another five had minor responses, 
which were not sufficient to meet response evaluation criteria in solid tumours (RECIST) criteria 
(Eisenhauer et. al., 2009). The patient with stable disease was alive three years post trial, up until 
the time of publication, with positron-emission tomography (PET) scans revealing a 50% 
decrease in tumours (Rudin et. al., 2011). Shortly after, a second Phase I clinical trial was 
launched in cohort of children with neuroblastoma, rhabdomyosarcoma or other rare tumours 
with neuroendocrine features (Burke et. al., 2014). In part A of the trial, 13 patients were injected 
with 109, 1010 or 1011 vp/kg NTX-010, and in part B, patients were given oral (days 1 to 14) and 
intravenous (days 1 and 8) cyclophosphamide, in combination with two doses of 1011 vp/kg 
NTX-010. The study showed that NTX-010 was well tolerated with a single dose limiting 
toxicity event recorded. While no objective response was observed, six patients did show disease 
stabilisation. A rapid neutralising antibody response to NTX-010 was also shown in this trial 
(Burke et. al., 2014).  
 
Finally, a single Phase II clinical trial was undertaken in SCLC patients who had been stable or 
responding after a regimen of four cycles platinum-based chemotherapy (Molina et. al., 2013). 
Patients were randomised into Arm A or Arm B and treated with a single dose of 1x1011 vp/kg 
NTX-010 or the saline control respectively. Within Arm A there were three observed grade 4 
events, with none in Arm B. Between Arms A and B there was no difference in progression-free 
survival and overall survival was only marginally different in Arm A (83%) vs. Arm B (85%). 
This clinical trial was also put on hold while the death of one patient was confirmed not to have 
been caused by NTX-010 treatment (Molina et. al., 2013). 
 
The results of the two Phase I clinical trials and the single Phase II clinical trial seemed to be 
at odds with each other, and with the promising results of the in vitro and in vivo trials. It 
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seemed then, that there was a lack of knowledge with respect to the defining characteristic that 
determined the distinct cellular susceptibility to SVV-001. In 2017 however, this defining 
characteristic was discovered. This was that the cellular receptor for SVV-001 is Anthrax Toxin 
Receptor 1 (ANTXR1), known also as Tumour Endothelial Marker 8 (TEM8) (Miles et. al., 
2017). This provides a key criterion by which future clinical trials can select patients who might 
benefit from NTX-010 therapy. ANTXR1 is a useful receptor in cancer therapy as it is 
upregulated in 60% of human cancers, and only weakly expressed in healthy cells (Miles et. 
al., 2017). That being said, ANTXR1 expression is necessary but not sufficient for successful 
infection and lysis of cancer cells (Miles et. al., 2017). Interestingly, the genome-less procapsid 
of SVV can also bind ANTXR1 (Strauss et. al., 2018).  
 
1.4.3 An emerging porcine pathogen 
As previously alluded to, SVV-001 was first isolated as a contaminant of cell culture. SVV-
001 was thought to be introduced through porcine trypsin, which is used to detach cells from 
culture vessels. This is because SVV has been shown to cause mild, self-limiting disease in 
pigs, with the exception of neonatal piglets, for whom SVV infection can be lethal (Segales et. 
al., 2017). The mild disease experienced by older pigs is characterised by the formation of 
vesicles around the mouths and coronary bands, which when the aetiological agent is not 
known, is termed porcine/swine idiopathic vesicular disease (PIVD/SIVD) (Singh et. al., 
2012). 
 
Currently, Clade III SVV is causing disease in pigs from Canada (Pasma, Davidson & Shaw, 
2008), the United States (Zhang et. al., 2015), Colombia (Sun et. al., 2017), Brazil (Leme et. 
al., 2015), Thailand (Saeng-Chuto et. al., 2018) and China (Zhao et. al., 2017). While the 
disease that SVV causes in these countries is not of concern in and of itself, it is clinically 
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indistinguishable from foot and mouth disease, thereby forcing immediate and costly 
quarantine and investigation of afflicted animals.  
 
1.5 Project 
This project comes in the context that cancer is highly prevalent, causing millions of deaths 
every year. This is despite the advances that have been made with respect to diagnosis of cancer 
and its treatment with surgery, chemotherapy and radiation therapy. In addition, each of these 
medical interventions comes with their own side effects which can significantly reduce the 
quality of life of treated persons. To address the bipartite problem of cancer mortality and the 
inefficacy and toxicity of contemporary treatments, new treatments are needed that are 
conversely effective and non-toxic.  
 
The necessity for new safe and effective treatments has born a number of promising therapies 
such as immunotherapy and the use of oncolytic viruses. Within the broad range of viral taxa 
that are employed for oncolytic virotherapy are a family of small, positive-sense RNA viruses, 
called picornaviruses. A number of naturally occurring and engineered picornaviruses have 
been investigated for their potential use as cancer therapeutics, but the subject of this particular 
project is Seneca Valley virus (SVV), a naturally occurring virus endemic in pigs. SVV has a 
selective tropism for cells expressing Anthrax Toxin Receptor 1 (ANTXR1), otherwise known 
as Tumour Endothelial Marker 8 (TEM8), which is upregulated in many cancers.  
 
ANTXR1 is necessary, but not sufficient, for the successful infection, intracellular replication 
and subsequent lysis of host cells by SVV. This means that there are cancers to which SVV 
can attach and infect, but not destroy. To increase the range of cancers that are potentially 
treatable by SVV, it has been proposed that the empty capsids of SVV, which can still bind 
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ANTXR1, be utilised as drug delivery vectors to deliver cytotoxic drugs / prodrugs. Among 
the primary issues with this idea is the intrinsic instability of the SVV empty capsids. To 
facilitate SVV’s use as a drug delivery vector then, there needs to be a way to stabilise these 
empty capsids.  
 
The aim of this project is to identify the residues and mutations thereof that confer increased 
stability to the capsid of SVV-001, and the mechanisms by which this occurs. 
 
We hypothesise that the inherently error-prone process of SVV viral replication, which brings 
about the quasispecies phenomenon, will inevitably produce SVV virions with increased 
stability. We plan to use exposure to heat to select for these hypothetical thermostable virions 
out of the heterogeneous population, and on purification and sequencing, determine how they 
compare to the wild-type. We will then explore this difference. 
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2 Methods and Materials 
 
2.1 Cells and virus 
2.1.1 Cell culture reagents and materials 
R10 media: Roswell Park Memorial Institute 1640 medium (GibcoTM, Fischer scientific 
catalogue number: 11-875-127) plus 20mM HEPES and 3.7 g L-1 NaHCO3. 
FBS: Foetal Bovine Serum. Moregate FCS, Lot#29827102 
2.1.2 Sub-culturing reagents 
TrypLE (ThermoFisher Scientific catalogue number: 12563-029) 
PBS: Phosphate Buffered Saline 
15 mL falcon tubes (Greiner Bio-One CELLSTAR catalogue number: 188271) 
T25 25 cm2 cell culture vessel (Greiner Bio-One CELLSTAR reference number: 690160) 
T75 75 cm2 cell culture vessel (Greiner Bio-One CELLSTAR reference number: 658170) 
10 mL tissue culture pipette (Greiner Bio-One CELLSTAR reference number: 607180) 
 25 mL tissue culture pipette (Greiner Bio-One CELLSTAR reference number: 760180) 
2.1.3 Sub-culturing protocol 
When cells had grown to confluence, commonly every 3-4 days, the media was decanted from 
the T75 culture vessel. The cells were then washed with PBS twice. 0.5 mL of TrypLE was 
then added to the cells and they allowed to incubate for a few minutes at 37 °C + 5% CO2. 2 
mL of cell line appropriate growth media was added and pipetted up and down to ensure 
detachment of cells from the T75 tissue culture vessel. The cells and media were then 
transferred to a sterile 15 mL falcon tube using a 10 mL pipette. The 15 mL falcon tube was 
centrifuged for 5 minutes at 1,200 rpm. Without disturbing the cellular pellet, the media was 
decanted. The pellet was then brought up to a single cell suspension in 9 mL by pipetting up in 
down with a 10 mL tissue culture pipette. A confluent tissue culture vessel would be split 1:3 
by 6mL of the cell suspension for being used for other experiments / or discarded. The 
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remaining 3 mL was then re-seeded in a T75 with 10mL fresh media and the cell line, media, 
date and passage number were recorded on the vessel.  
2.1.4 Cell counting 
A clean cover slip was placed on a haemocytometer. From a 15 mL falcon tube containing a 
single cell suspension of cells and media, a small volume (10 μL for one reading, 20 μL for 
two readings on the same haemocytometer) was taken from the falcon tube and loaded onto 
the haemocytometer. The haemocytometer was then examined under a light microscope, the 
cells in the grid counted and the cell numbers enumerated with the following formula. 
𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟𝑠 = 𝐶𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑥
1
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
 𝑥 10,000 𝑥 𝑉𝑜𝑙𝑢𝑚𝑒 𝑖𝑛 𝑓𝑎𝑙𝑐𝑜𝑛 𝑡𝑢𝑏𝑒 
2.1.5 Viral strains 
Initial stocks of SVV-001 kindly provided by collaborators Linde A. Miles and John T. Poirier 
from the Molecular Pharmacology Program and Department of Medicine, Memorial Sloan 
Kettering Cancer Center, New York, New York, USA. SVV-001 was further amplified and 
isolated in the Bostina Lab. 
 
2.2 Plaque formation assay 
2.2.1 Plaque assay: reagents and materials 
R10 media (GibcoTM, Fischer scientific catalogue number: 11-875-127) 
FBS: Foetal Bovine Serum. Moregate FCS, Lot#29827102 
Tissue culture agarose (Lonza catalogue number: 50100) 
12-well plates (Greiner Bio-One CELLSTAR reference number: 665180) 
2.2.2 Plaque formation assay: protocol 
Individual wells of 12 well plates were seeded with H446 cells in 1 mL R10 + 10% FBS and 
allowed to attach overnight. The next day the medium was removed, replaced with 100 µL, 10-
fold serial viral dilutions in R10 media + 2% FBS or media only controls. They were allowed 
to incubate for an hour with regular stirring. The media was then removed from the wells and 
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replaced with 1 mL 2X R10 + 2% FBS + 1% agarose. This was allowed to set overnight while 
incubating at 37 °C + 5% CO2. After 24 hours, plaques were counted and viral titres were 
derived from the following equation.  








2.3 Thermal stability probe 
2.3.1 Thermal stability probe reagents 
R10 media (GibcoTM, Fischer scientific catalogue number: 11-875-127) 
Bio-Rad T100TM Thermal Cycler (Bio-Rad, Hercules, California, USA) 
0.2 mL PCR tubes (Lab supply catalogue number: AXY321-01-102) 
2.3.2 Thermal stability probe protocol 
Initial method 
50 µL of 1:50 dilutions of a 5x1010 PFU/mL SVV-001 stock in 0.2 mL PCR tubes were 
sonicated and heated to desired temperatures in thermocycler for 30 minutes and cooled back 
down to 12 °C. The viral titres of the heated samples, as well as unheated controls were 
enumerated using plaque formation assays (See: 2.2 Plaque formation assay). 
Revised method 
From a 1:1000 dilution of a 5x1010 PFU/mL SVV-001 stock, paired 50 µL samples were taken, 
one would be heated to the desired temperature in a thermocycler for 30 minutes, and the other 
kept at room temperature for the same time. Both were then enumerated with plaque formation 
assays (See: 2.2 Plaque formation assay).  
 
2.4 Selection for thermostable viral mutants  
2.4.1 Selection for thermostable viral mutants: reagents and materials 
0.2 mL PCR tubes (Lab supply catalogue number: AXY321-01-102) 
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Bio-Rad T100TM Thermal Cycler (Bio-Rad, Hercules, California, USA) 
50,000 MWCO centrifugal filters (Amicon reference number: UFC805024) 
T25 25 cm2 cell culture vessel (Greiner Bio-One CELLSTAR reference number: 690160) 
2.4.2 Selection for thermostable viral mutants: protocol 
Viral samples in 0.2 mL PCR tubes were heated to desired temperatures in thermocycler for 
30 minutes and cooled back down to 12 °C. The viral titres of the heated samples, as well as 
unheated controls were enumerated using plaque formation assays (See: 2.2 Plaque formation 
assay). Virus from the heated sample was infected at an MOI of 0.1 through a confluent T25 
containing approximately 1.72x106 H446 cells. The virus was allowed to infect the cells over 
48 hours. The flasks were then collected and freeze-thawed three times at -80 °C to lyse the 
cells. The cell debris was separated from the supernatant by centrifugation for 5 minutes at 
3,000 rpm. The supernatant was then passed through a 50,000 molecular weight cut-off filter. 
The bulk liquid that passed through the filter was discarded and the liquid that didn’t pass 
through was resuspended in 100 µL R10 media + 2% FBS. This was further divided into two 
0.2 mL PCR tubes, one which would then serve as the unheated control and one which would 
then be heated and titred as before.  
 
2.5 Viral purification 
2.5.1 Optiprep® viral purification: reagents and materials  
R10 media (GibcoTM, Fischer scientific catalogue number: 11-875-127) 
FBS: Foetal Bovine Serum. Moregate FCS, Lot#29827102 
T175 175 cm2 culture vessels (Greiner Bio-One CELLSTAR reference number: 660160) 
60% Optiprep stock solution (Axis Shield product number: 1114542) 
250 mL Nalgene bottles (ThermoFisher catalogue number: 2103-0008) 
Beckman Coulter Avanti J-26 XP1 high-speed centrifuge (Beckman Coulter, Indianapolis, 
USA) 
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Fiberlite F250 rotor (ThermoFisher Scientific Waltham, Massachusetts, USA) 
Beckman Coulter Optima XPN-80 ultracentrifuge (Beckman Coulter, Indianapolis, USA) 
Beckman Coulter SW32.1 Ti rotor (Beckman Coulter, Indianapolis, USA) 
Beckman 16.8 mL polypropylene tubes (Beckman Coulter reference number: 337986) 
Beckman 36 mL polypropylene tubes (Beckman Coulter reference number: 326823) 
2.5.2 Optiprep® viral purification: protocol 
H446 cells were grown to confluence in six T175 culture vessels containing 35mL R10 + 10% 
FBS. The growth media in each culture vessel was replaced with 25 mL infection media 
containing 20 mL R10 + 2% FBS and 5mL R10 + 2% + 1 µL SVV 1:40 µL viral dilution in 
R10. The cells and virus were incubated at 37 °C + 5% CO2 for 48 hours, or until complete 
cytopathic effect was observed. The cells were then freeze-thawed from -80 °C to room 
temperature repeatedly to lyse the cells. The media containing virus and cells from all of the 
culture vessels were combined in 250 mL Nalgene bottle(s) and balanced with Nalgene 
bottle(s) containing water. The Nalgene bottles were centrifuged at 10,000 g for 1 hour at room 
temperature using a Fiberlite F250 rotor in a Beckman Coulter Avanti J-26 XP1 high-speed 
centrifuge. The virus containing supernatant was collected and the cell debris pellet was stored 
at 4 °C. The virus containing supernatant was added to 36 mL tubes, balanced and placed in 
Beckman Coulter SW 32 buckets. They were then spun down for 2 hours at 28,500 rpm using 
a Beckman Coulter SW32.1 Ti rotor in a Beckman Coulter Optima XPN-80 ultracentrifuge. 
The supernatant was decanted and stored at 4 °C. The viral pellet was covered with 200 µL 
sterile PBS and stored overnight. The following day the viral pellet was vigorously resuspended 
and loaded into a 17 mL tube containing 25% optiprep solution, underlaid with 2mL 50% 
optiprep. The tubes were loaded into SW 32.1 buckets and centrifuged for 1 hour at 28,500 
rpm using a Beckman Coulter Optima XPN-80 ultracentrifuge. The viral band on the interface 
of the 25% and 50% optiprep solutions was then disturbed by pipetting up and down, and the 
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tubes spun down for 18 hours at 28,500 rpm using a Beckman Coulter Optima XPN-80 
ultracentrifuge. Virus from observed bands was then collected and visualised under 
transmission electron microscopy (see: 2.12: Transmission electron microscopy). 
 
2.5.3 Caesium chloride viral purification: reagents and materials 
R10 media (GibcoTM, Fischer scientific catalogue number: 11-875-127) 
FBS: Foetal Bovine Serum. Moregate FCS, Lot#29827102 
T175 175 cm2 culture vessels (Greiner Bio-One CELLSTAR reference number: 660160) 
Caesium Chloride (Serva product number: 15554) 
250 mL Nalgene bottles (ThermoFisher catalogue number: 2103-0008) 
Beckman Coulter Avanti J-26 XP1 high-speed centrifuge (Beckman Coulter, Indianapolis, 
USA) 
Fiberlite F250 rotor (ThermoFisher Scientific Waltham, Massachusetts, USA) 
Beckman Coulter Optima XPN-80 ultracentrifuge (Beckman Coulter, Indianapolis, USA) 
Beckman Coulter SW32.1 Ti rotor (Beckman Coulter, Indianapolis, USA) 
Beckman 16.8 mL polypropylene tubes (Beckman Coulter reference number: 337986) 
Beckman 36 mL polypropylene tubes (Beckman Coulter reference number: 326823) 
2.5.4 Caesium chloride viral purification: protocol 
H446 cells were grown to confluence in ten T175 culture vessels containing 35mL R10 + 10% 
FBS. The growth media in each culture vessel was replaced with 25 mL infection media 
containing 20 mL R10 + 2% FBS and 5mL R10 + 2% + 1 MOI SVV in R10. The cells and 
virus were incubated at 37 °C + 5% CO2 for 48 hours, or until complete cytopathic effect was 
observed. The cells were then freeze-thawed from -80 °C to room temperature repeatedly to 
lyse the cells. The media containing virus and cells from all of the culture vessels were 
combined in 250 mL Nalgene bottle(s) and balanced with Nalgene bottle(s) containing water. 
The Nalgene bottles were centrifuged at 10,000 g for 20 minutes at room temperature using a 
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Beckman Coulter Avanti J-26 XP1 high-speed centrifuge. The cell-free supernatant was then 
removed and the cell pellet stored at 4 °C. The cell-free supernatant was then divided between 
six 36 mL Beckman polypropylene tubes and centrifuged at 120,000 g for one hour and 10 
minutes at 4 °C. This was done using SW32 buckets in a SW32.1 rotor. The supernatant was 
then collected and the viral pellets were allowed to resuspend overnight at 4 °C. The following 
day, the pellets were collected. CsCl gradients were formed by the addition of one part CsCl to 
two parts CsCl buffer. The density of the CsCl solution was measured by weighing a known 
volume and then checked for appropriateness against provided CsCl density vs. centrifugation 
speed graphs to prevent “bulleting”. Beckman 16.8 mL polypropylene tubes were first loaded 
with 6 mL CsCl solution and then 4 mL of CsCl buffer. In one of the tubes, resuspended viral 
pellets in CsCl were added and the remainder of the tube was filled with CsCl buffer. This was 
balanced against another tube filled with just CsCl. The two tubes were then centrifuged at 
22,000 rpm for 18 hours at room temperature. The CsCl around observed bands were collected 
and fractions were viewed under electron microscopy.  
 
2.6 Viral RNA isolation 
2.6.1 Viral RNA isolation: reagents and materials (Nucleospin) 
Nucleospin® RNA virus kit (Macherey-Nagel reference number: 740956.250) 
2.6.2 Viral RNA isolation: protocol (Nucleospin) 
The viral RNA isolation protocol was performed according to the Nucleospin® RNA virus 
protocol as follows. 150 µL of purified virus sample was combined with 600 µL RAV1 and 
heated to 70 °C for 5 minutes. This was then combined with 600 µL ethanol, loaded into the 
Nucleospin® column and spun down at 8,000 g for 1 minute. 500 µL RAW was added to the 
column and this too was spun down at 8,000 g for 1 minute, the flow-through was then 
discarded. 600 µL RAV3 was added to the Nucleospin® column and the flow-through was 
discarded, this was repeated with 200 µL RAV. The column was then loaded into a new sterile 
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1.5 mL microcentrifuge tube. RNAse-free H2O was heated to 70 °C and 50 µL was added to 
the column. This was then centrifuged at 11,000 rpm for 1 minute and the flow-through was 
collected.  
 
2.6.3 Viral RNA isolation: reagents and materials (QIAmp) 
QIAmp® Viral RNA Mini Kit (QIAGEN catalogue number: 52904) 
2.6.4 Viral RNA isolation: protocol (QIAmp) 
SVV RNA isolation was performed according to the QIAmp® kit directions as follows: 
560 µL buffer AVL with carrier RNA was combined with 140 µL sample in a 1.5 mL 
microcentrifuge tube. The microcentrifuge tube was then pulse-vortexed for 15 seconds and 
allowed to sit for 10 minutes at ambient temperature. This was then followed by centrifugation, 
addition of 560 µL ethanol, vortexing and another round of centrifugation. Two halves of the 
current solution (should be 630 µL) were added to two QIAmp mini columns inside two 2mL 
collection tubes. 560 µL of buffer AW1 was added to each of the tubes and they were 
centrifuged at 8,000 rpm for minute. The flow-through in the 2 mL collection tube was 
discarded and the same collection tube was replaced. 500 µL buffer AW2 was then added and 
centrifuged at full speed for 3 minutes. This step was then repeated as per kit recommendation. 
The 2 mL column was then replaced by a clean 1.5 mL microcentrifuge tubes and following 
the addition of 60 µL buffer AVE, were centrifuged for a final time for one minute at 8,000 
rpm. 
 
2.7 cDNA generation 
2.7.1 cDNA generation: reagents and materials 
High capacity cDNA reverse transcription kit (Applied Biosystems reference number: 
4368814) 
Bio-Rad T100TM Thermal Cycler (Bio-Rad, Hercules, California, USA) 
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0.2 mL PCR tubes (Lab supply catalogue number: AXY321-01-102) 
Primers: 
Pair 1 Forward TTTGAAATGGGGGGCTG 
Pair 1 Reverse GATAGACGGGATCTGAAAGGGTG 
Pair 2 Forward CTACCTCGGTAGACATAAAC 
Pair 2 Reverse GCTATTTGGTTCCAGTCTTTG 
2.7.2 cDNA generation: protocol 
Reaction mixtures were generated according to the following proportions 
• 2 µL RT buffer 
• 0.8 µL dNTP’s  
• 1.5 µL random primers 
• 0.5 µL specific primers 
• 1 µL reverse transcriptase 
• 4.2 µL H2O 
= 20 µL reaction mix 
Reaction mixtures were then heated according to the regime stipulated in Table 1. 
Table 1. Thermocycler regimen for cDNA generation 
Temperature 25 °C 37 °C 85 °C 4 °C 
Time 10 minutes 120 minutes 5 minutes  
 
 
2.8 PCR amplification 
2.8.1 PCR amplification: reagents and materials 
Bio-Rad T100TM Thermal Cycler (Bio-Rad, Hercules, California, USA) 
0.2 mL PCR tubes (Lab supply catalogue number: AXY321-01-102) 
Phision Hot Start II DNA Polymerase (ThermoFisher scientific catalogue number: F549L) 
5X Phusion HF buffer (Included with Phusion Hot Start II DNA polymerase) 
DMSO (Included with Phusion Hot Start II DNA polymerase) 
50 mM MgCl2 (Included with Phusion Hot Start II DNA polymerase) 
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Primers: 
Pair 1 Forward GGCAACATCCAACCTGCTTTTG 
Pair 1 Reverse TTTGTGAGGAGACCCGCTAATCC 
Pair 2 Forward TTCAGTAGACTTCTCGACCTCCTC 
Pair 2 Reverse AGGAGTTCTGTGTCTCTGAGGATTG 
Pair 3 Forward GTCCCAATTTCATCAACCCCTATCAAG 
Pair 3 Reverse TTGTGCAGGCTAAACCAACCATCAG 
Pair 4 Forward CTACATCTCGCCCAGTGACTACC 
Pair 4 Reverse TGTTTTACAGCGGTGCTTTTCTTCTC 
Pair 5 Forward CATGCTGATTGGGGGACTATTTACG 
Pair 5 Reverse GCAGCTATTTGGTTCCAGTCTTTGAC 
2.8.2 PCR amplification: protocol 
Reaction mixtures were generated according to the following proportions 
• 12.4 µL H2O 
• 4 µL buffer 
• 0.4 µL dTNP’s (10mM) 
• 0.2 µL Phusion Hot Start II DNA polymerase 
• 1 µL forward primer 
• 1 µL reverse primer 
• 1 µL template cDNA 
= 20 µL reaction mix 
Table 2. Thermocycler regimen for PCR amplification of wild-type and putative SVV-001 
mutant genomes  
  40x Cycles  
Temperature 98 °C 98 °C 55 °C 72 °C 12 °C 
Time 30 seconds 7 seconds 30 seconds 45 seconds  
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2.8.3 Gel electrophoresis 
PCR reaction mixes were combined with 1 µL 5X loading dye and subjected to 
electrophoresis through 2% agarose gels at 60 V until the dye fronts had migrated the length 
of the gel, taking somewhere between 75-90 minutes. Gels were visualised with a Cambridge 
Uvitec gel doc. 
2.8.4 Gel extraction 
Gel extraction of the PCR fragments of interest were performed using a QIAGEN MinElute® 
Gel extraction kit (QIAGEN catalogue number: 28604) according to the supplied protocol. 
This was as follows: DNA fragment was excised with a clean, sharp scalpel and placed in a 1.5 
mL microcentrifuge tube. The gel fragment was then weighed and three parts buffer QG was 
added to one part gel slice. The contents of the microcentrifuge tube were then heated to 50 °C 
with regular stirring until the gel fragment was completely dissolved. One gel volume’s worth 
of isopropanol was then added and mixed by inversion. The liquid was then added to a 
MinElute column inside a 2 mL collection tube and centrifuged for 1 minute at 13,000 rpm. 
500 µL of buffer QG was added and the column was centrifuged for a further 1 minute at 
13,000 rpm. This was followed by the addition of 750 µL of buffer PE and centrifugation at 
13,000 rpm for 1 minute. The column was then allowed to stand for 2-5 minutes before being 
centrifuged again at 13,000 rpm. The MinElute column was then placed in a sterile 1.5 mL 
microcentrifuge tube, and 10 µL buffer EB was added to the column before a final 
centrifugation at 13,000 rpm for 1 minute. The column was then removed and the eluted DNA 
stored at -4 °C.  
 
2.9 Sequencing  
2.9.1 Sequencing: reagents and materials 
MilliQ water 
0.2 mL PCR tubes (Lab supply catalogue number: AXY321-01-102) 
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2.9.2 Sequencing: protocol 
Gel extracted PCR products were measured for protein concentration using a Nanodrop. 5 µL 
reaction mixtures were made according to the following proportions. 
• 1 ng per 100 bp PCR product per 5 µL  
• 3.2 pmol primer per 5 µL  
These samples were submitted to Genetic Analysis Services and the results were analysed 
using DNASTAR Seqman Pro software.  
 
2.10 In silico analysis of putative thermostability mutations 
2.10.1 Visualisation of viral capsid structures with UCSF Chimera 
Viral structures were accessed using protein database accession numbers. Using in-built tools, 
the changes in internal binding were shown between the wild-type and mutant (Petterson et. 
al., 2004). Contacts between residues were defined by having a Van Der Waal overlap of -0.4 
Å or greater. 
2.10.2 Prediction of protein stability change using DUET 
DUET utilises two methods to predict the change in protein stability due to mutation (Pires, 
Ascher & Blundell, 2014). The first is SDM, which utilises environment-specific substitution 
tables (ESSTs) to calculate change in thermal stability of proteins on mutation (Pandurangan 
et. al., 2017). The second is mCSM (Pires, Ascher & Blundell, 2013). The basis of mCSM 
protein stability prediction is the use of graph-based signatures representing the distance 
between atoms (Pires, Ascher & Blundell, 2013). 
 
2.11 Transmission electron microscopy 
2.11.1 Transmission electron microscopy: reagents and materials 
1% Uranyl Acetate (pH 4) 
Phosphotungstic acid 
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2.11.2 Transmission Electron Microscopy: protocol 
2.11.2.1 Sample preparation 
Copper grids were glow-discharged. The copper grids were then treated with 5 µL sample and 
allowed to sit for 1 minute before being blotted off. The copper grids were then treated with 5 
µL of either 1% Uranyl Acetate (pH 4) or Phosphotungstic Acid for 1 minute, before blotting 
the liquid off.  
2.11.2.2 Image collection 
Philips CM100 BioTWIN transmission electron microscope with a LaB6 emitter (Philips/FEI 
Corporation, Eindhoven, Holland) running at 100 kV. Images were acquired using a 
MegaView lll digital camera (Olympus Soft Imaging Solutions GmbH, Münster, Germany). 
 
2.12 SDS-PAGE gel analysis  
2.12.1 SDS-PAGE gel analysis: reagents and materials 
MilliQ water 
100% Methanol 
500 mM DTT (Dithiothreitol) 
NuPAGETM LDS Sample Buffer (ThermoFisher Scientific catalogue number NP0007) 
Chloroform 
Bolt™ 4-12% Bis-Tris Plus Gel (Invitrogen catalogue number: NW04120BOX) 
ECLTM RainbowTM Full Range Protein Marker (GE Healthcare product number: RPN800E) 
SeeBlueTMPlus2 Pre-stained Protein Standard (Thermofisher scientific catalogue number: 
LC5925) 
QubitTM protein assay kit (ThermoFisher Scientific catalogue number Q33211) 
QubitTM assay tubes (ThermoFisher Scientific catalogue number Q32856) 
Qubit 1.0 flurometer (ThermoFisher Scientific Waltham, Massachusetts, USA) 
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2.12.2 SDS-PAGE gel analysis: protocol 
2.12.2.1 Protein Precipitation 
In a 1.5 mL microcentrifuge tube, 150 µL of purified virus in solution was combined with 650 
µL methanol and mixed well. This was combined with 150 µL chloroform and vortexed. 450 
µL of milliQ water was also added and the microcentrifuge tube was vortexed again. The liquid 
was then centrifuged at 13,000 rpm for 5 minutes. This resulted in a white band between and 
upper and lower volumes. The upper volume was removed and a further 650 µL of methanol 
was added. The microcentrifuge tube was inverted 3 times and centrifuged at 13,000 rpm for 
5 minutes. The pellet was resuspended overnight in 20 µL milliQ water.  
2.12.2.2 Sample preparations 
The 20 µL of resuspended protein from the previous step was combined with 6.66µL 
NuPAGETM LDS Sample buffer and 2.66 µL 500 mM DTT. The 1.5 mL microcentrifuge 
tube containing the resuspended protein was then heated to 90 °C for 10 minutes.  
2.12.2.3 Qubit assay 
Qubit protein buffer was made by addition of 1 part QubitTM protein reagent to 200 parts 
QubitTM protein buffer. Protein standards were made by adding 10 µL of supplied protein 
solutions in 190 µL Qubit protein assay buffer. Samples were measured with 1 µL prepared 
protein sample in 199 µL Qubit protein buffer. The standards were first measured with a Qubit 
1.0 fluorometer to generate Bradman curves. The fluorescence from the samples were then 
measured against the Bradman curves to derive the concentration of protein in the samples.  
2.12.2.4 Gel electrophoresis 
Gel tanks were almost completely filled with 1X MES. The sticker on the reverse of a Bolt™ 
4-12% Bis-Tris Plus Gel was removed and the gel itself inserted into the gel tank, fixed in place 
with the cassette clamps. The comb from the Bolt™ 4-12% Bis-Tris Plus Gel was removed 
and the tank filled to the indicated level so as to fill the wells of the Bolt™ 4-12% Bis-Tris 
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Plus Gel. Viral protein samples and ECLTM RainbowTM Full Range Protein Marker were loaded 
into wells of the gel. Gels were run under a constant voltage of 70 V until dye fronts had 
migrated through the length of the gel (usually one and a half hours). The gels were removed 
from the tank and the plastic casing cracked open. The gel was placed in a plastic tray with 
coomassie blue colloidal stain and left to stain overnight. The stained gel was then destained 
and viewed under the Uvitec Cambridge gel doc. 
2.12.3 ImageJ: Fiji analysis 
Image J is an extensible open-source program for the analysis of scientific images. Image J: 
Fiji contains a number of additional plugins particularly suited to the analysis of biological 
images based on common biology techniques (Schindelin et. al., 2012). Once SDS PAGE gels 
were photographed, Image J: Fiji was used to determine the varying ratios of capsid proteins 
present in the wild-type and thermally selected populations. For more information on how this 
was done, refer to (7.2 ImageJ Fiji analysis of SDS PAGE gels). 
 
2.13 Mass spectrometry 
2.13.1 Mass spectrometry protocol 
Gel bands were extracted with a sterile scalpel and were submitted in sterile 1.5 mL 
microcentrifuge tubes to Otago’s Centre for Protein Research (CPR). MALDI tandem Time-
of-Flight (MALDI-TOF) Mass Spectrometry was used to analyse the submitted protein bands 
and the results were checked against MASCOT and SEQUEST search engines.  
 
2.14 Particle Stability Thermal Release assay (PaSTRy) 
2.14.1 PaSTRy: reagents and materials 
QubitTM protein assay kit (ThermoFisher Scientific catalogue number Q33211) 
QubitTM assay tubes (ThermoFisher Scientific catalogue number Q32856) 
Qubit 1.0 flurometer (ThermoFisher Scientific Waltham, Massachusetts, USA) 
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MicroAmp® Fast Optical 96-well Reaction Plate (Applied Biosystems reference number: 
4346906) 
20X SYTO9 (ThermoFisher Scientific catalogue number: S34854) 
30X SYPRO Orange (ThermoFisher Scientific catalogue number: S6650) 
Applied Biosystems Viia7 qPCR (Applied Biosystems, Carlsbad, California, USA) 
2.14.2 PaSTRy: protocol 
Protein in virus solution was measured using a Qubit 1.0 fluorometer (see: 2.12.2.3: Qubit 
assay) to determine the volume necessary for 1 µg total viral protein. Wells of 96-well plates 






Table 3: Reaction mixtures for PaSTRy  
56 °C resistant 





56 °C resistant SVV + 
hydrophobic residue 
binding dye 
56 °C resistant SVV 
+ hydrophobic 
residue binding dye 
6 µL purified viral 
fraction 
3 µL 20X SYTO9 
11 µL PBS 
4 µL purified viral 
fraction 
3 µL 20X SYTO9 
13 µL PBS 
2 µL purified viral 
fraction 
2 µL 30X SYPRO 
Orange 
16 µL PBS 
2 µL purified viral 
fraction 
2 µL 30X SYPRO 
Orange 
16 µL PBS 
 
Reaction mixtures were heated from 25 °C to 95 °C in 0.5 °C increments with a 30 second 
resting step at each temperature. 2 minute holding steps were used at 25 °C to 95 °C, but 
fluorescence was not measured during these steps.  
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2.15 Cryo-electron microscopy 
2.15.1 Cryo-electron microscopy reagents and materials 
JEOL 2200FS Cryo-TEM (JEOL ltd., Tokyo, Japan)                        
FEI Vitrobot Mark IV (FEI, Hillsboro, Oregon, USA) 
C-flat grids CF-2/1-2C-50 (Electron microscopy sciences catalogue number: E13557) 
100,000 NMWL filters (Amicon reference number: UFC510024) 
GloQube glow discharger (Quorum technologies, Lewes, UK) 
2.15.2 Cryo-electron microscopy protocol 
Sample Preparation 
CsCl purified 56 °C resistant thermostable SVV-001 mutant was concentrated by passing 
isolated fractions through 100,000 NMWL filters and resuspension in PBS. C-flat grids were 
glow discharged for 60 seconds at a constant current of 5 mA using a GloQube glow discharger. 
3.5 µL of purified thermostable SVV mutant in PBS was added to the C-flat grids and the 
excess liquid was blotted off with a FEI Vitrobot Mark IV at 100% humidity for 3.5 seconds 
with blot force 0. Immediately following blotting, grids were plunge frozen in liquid ethane at 
-180 °C. Frozen grids were transferred into grid storage boxes and stored in liquid nitrogen 
until imaging. 
Image acquisition 
Frozen grids were imaged at 20,000x or 25,000x magnification on a JEOL 2200FS Cryo-TEM 
operating at 200 kV. Movie frames were recorded with a DE-20 direct electron detector. Grid 
areas were selected on the basis of optimal ice thickness. Montages were taken of grid areas 
with thin ice, which provides a low-magnification overview of the available grid holes for 
imaging. Grid holes within grid areas containing vitreous ice and particles were manually 
labelled for image acquisition. Figure 8 below is included to distinguish between the some of 
the terminology used in describing areas and/or sub-areas within C-flat grids. 
 62 
 
Figure 8: C-flat grid structure. C-flat grids as they appear under increasing magnification, 
from the whole grid, to a representation of how a grid hole appears in a micrograph taken at 
20,000x magnification. 
 
2.15.3 Single Particle Analysis 
The data collected from cryo-electron microscopy investigation of 56 °C resistant SVV 
mutants was analysed using Relion 3.0 software. First, a total of 18 movie frames were aligned, 
a process which is performed to correct for motion of particles induced by agitation from the 
electron beam. Each movie frame had a total dose of 2.78 el/Å2/frame, culminating in a total 
dose of 50 el/Å2/image. Particles of interest were manually picked using in-built software tools. 
The picked particles were then Contrast Transfer Function (CTF) corrected. CTF correction is 
undertaken to adjust for sub-optimal imaging conditions using the Scherzer formula as below: 
𝛾(𝑘) = 𝜋 2⁄ (𝐶𝑠𝜆
3𝑘4 − 2∆𝑧𝜆𝑘2) 
Where: γ(k) = Phase shift 
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k = Scattering vector 
CS = Spherical aberration coefficient of the microscope 
λ = Wavelength of the electron beam 
∆z = Defocus 
 
The Scherzer formula determines phase shift as a result of defocus and spherical aberration, 
which when corrected for provide an image that better represents the sample. After CTF 
correction, 2D classes of picked particles /were iteratively generated to filter out particles that 
were not examples of full, packaged virions. Once 2D classes were determined to be of 
sufficient quality, 3D classification was performed using a a low-pass filtered 30 Å structure 
of the SVV-001 (Electron Microscopy Data Bank accession number: 7110) and imposing I4 
symmetry. A gold-standard fourier shell cut-off of 0.143 was then used to estimate the 




3.1 Thermal probe 
3.1.1 Susceptibility of wild-type SVV to varying incubation temperatures.  
Before attempting to select for a thermostable mutant, it was prudent to characterise the 
thermostability of wild-type SVV-001. This was to inform the temperature for the regime of 
heating and passage to select for the mutants, and provide a reference to which any generated 
mutants could be compared. Figure 3 shows SVV viral titres remained stable when heated for 
30 minutes at temperatures between 37 °C and 55 °C, with SVV viral titre declining sharply 
with incubation temperature exceeding 56 °C. At 58.5 °C, there was a 100-fold decrease in 
viral titre which would be used in forthcoming experiments to select for thermostable SVV 
mutants.  
 



























Figure 9: Heating at 58.5 °C reduces SVV viral titre 100-fold. From a 5x1011 PFU/mL stock 
of purified SVV, 1:50 µL dilutions were aliquoted and heated at various temperatures for 30 
minutes before being cooled to 12 °C and titred by plaque assay. 
 
3.1.2 Susceptibility of wild-type SVV to varying incubation temperatures (revised method)  
To gain a clearer idea as to the temperature required to exert a significant pressure on wild-
type SVV-001, the methodology was amended to include a comparison of the heated samples 
and analogous unheated controls, rather than comparing viral titres of the heated samples to 
the titre of the stock from which they were derived. This was done in light of conflicting results 
from the previously discussed thermal probe experiments and the initial thermal selection 
experiment (see: 3.2.1 Thermal selection of SVV-001). Figure 10 shows a statistically 
significant approximately 200-fold decrease in SVV viral titre when heated to 53.5 °C.    
 
Figure 10: Heating at 53.5 °C significantly reduces SVV viral titre. Aliquots of SVV-001 
in solution were added in equal volumes to PCR tubes and of paired samples, one was heated 
to the desired temperature for 30 minutes and the incubated other at room temperature for 30 
minutes. The viral titres of the two samples were enumerated with plaque assays and the 
difference plotted above.  
 





3.2 Thermal selection  
3.2.1 Thermal selection of wild-type SVV-001 
Following the initial temperature probe, wild-type SVV-001 was passaged through H446 cells 
and heated to 58.5 °C. Contrary to the results of the first temperature probe, Figure 11 shows 
that when heated to 58.5 °C for 30 minutes, SVV-001 viral titre would drop below the limits 
of detection, inferring much greater loss in viral titre than 100-fold. This experiment was the 
basis for the need to revise the method for the thermal probe (see: 3.1.2 Thermal probe). This 
experiment did show that SVV-001 titre could be maintained at similar levels when passaged 
without heating at 0.1 MOI.  
 
Figure 11: Heating at 58.5 °C for 30 minutes produced a single SVV viral plaque. SVV-
001 was inoculated into a confluent T25 culture vessel of H446 cells (approximately 1.72 x 
106 cells) at MOI 0.1. After separation from cells by freeze-thawing and centrifugation, virus 
in solution were heated to 58.5 °C and titred with plaque assays. Passage without heating is 
shown in black, while red lines denote heating.  
 
One viral plaque was observed in a plaque assay of the undiluted heated viral sample. As this 
plaque was thought to represent a uniquely thermostable viral population, the plaque was 
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extracted from the well using a 20 µL – 200 µL pipette tip and grown in a confluent T25 of 
H446 cells. The virus from this plaque will be referred to as the plaque purified viral population 
in forthcoming experiments.  
 
3.2.2 Thermal selection for a 58.5 °C resistant mutant from plaque-purified viral population 
As the plaque-purified viral population was initially derived from a plaque that remained after 
exposure of wild-type SVV-001 to incubation at 58.5 °C, we investigated whether this 
population remained resistant to heating at this temperature. Figure 12 shows that initially, this 
was not the case, though this plaque purified viral population was more resistant to heating at 
58.5 °C than the wild-type, there still remained a significant difference between the pre- and 
post-heated viral titres. This trend continued for 10 cycles of heating and passage, with no 
apparent adaption of the plaque purified viral population to heating at 58.5 °C. At this time, 
attempts to select for increased thermal stability were ceased.  
 
Figure 12: Plaque purified virus showed no adaptation to heating at 58.5 °C. Titres of pre- 
and post-heated virus were enumerated with plaque assays and surviving virus post-heating 
was passaged through H446 cells, forming the next passage’s pre-heated virus. After the initial 
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passage, experiments were performed in triplicate and statistically analysed with paired 
student’s T-test.   
 
3.2.3 Thermal selection for a 56 °C resistant SVV-001 mutant from plaque-purified viral 
population 
Though selection with the plaque purified viral population failed to produce a viral mutant that 
was completely resistant to heating at 58.5 °C, it was reasoned that as there was a similar loss 
in viral titre when heating the wild-type to 53.5 °C, that this plaque purified viral population 
might be completely resistant to heating at temperatures lower than 58.5 °C, but higher than 
53.5 °C. Figure 13 shows that the plaque purified viral population remained stable across three 
successive passages after heating to 56 °C.  
 
Figure 13: Plaque purified virus was completely resistant to heating at 56 °C. Titres of 
pre- and post-heated virus were enumerated with plaque assays and surviving virus post heating 
was passaged through H446 cells, forming the next passage’s pre-heated virus. Experiments 
were performed in triplicate and statistically analysed with paired student’s T-test.   
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3.3 Viral purifications 
3.3.1 Viral purification by ultracentrifugation through Optiprep® gradient 
The viral populations shown in the thermal selection experiments to have a higher tolerance to 
heating were grown to high titres in H446 cells before being purified by Optiprep® or caesium 
chloride gradient. Figure 14 below provides an example of a viral band, which is somewhat 
difficult to see, but lies between the interface (strong white band) and the point at which the 
curved and cylindrical portions of the Beckman tubes intersect. Figure 8 also shows electron 
micrographs taken from two separate purifications of the 56 °C resistant viral population and 
58.5 °C selected viral population.  
  
 
Figure 14: Viral purification of 56 °C resistant and 58.5 °C selected viral populations. A) 
An example of a viral band following the final step in viral purification. B) Electron micrograph 
of purified 56 °C resistant virus. C) Electron micrograph of purified 58.5 °C virus. D) Electron 






3.4 PCR amplification 
3.4.1 SVV-001 and putative thermostable mutants  
The RNA from wild-type SVV-001 and 56 °C resistant viral populations were extracted using 
a Nucleospin® RNA virus kit. This was used as the template for the generation of two cDNA 
products which together are analogous to P1, that included part of the 5’ UTR and part of P2 
(See: 2.8 cDNA generation). This cDNA was then expanded in five separate PCR reactions as 
described in methods (See: 2.9 PCR amplification). As the third set of PCR primers targeted 
an area of overlap between the two cDNA constructs, either of the two could be used as a 
template for PCR. For this reason, both cDNA constructs were used as templates, generating 
similarly sized PCR products. Figure 11 shows the process of preparing the SVV capsid 
encoding region for sequencing, including gel electrophoresis of PCR reactions of wild-type 
SVV-001, 56 °C resistant and 58.5 °C selected viral populations. 
 


















      
Figure 15: Workflow of the preparation of the wild-type, 56 °C resistant and 58.5 °C 
selected viral populations for sequencing. A) cDNA from the capsid coding region of SVV-
001 and thermostable populations was generated in two halves. Using the two cDNA constructs 
as templates, the capsid coding region of SVV-001 and thermostable populations were 
expanded in five PCR reactions. B) PCR reactions expanding the first two segments of each of 
the 56 resistant and wild-type viral populations. C) PCR reactions expanding the remaining 
segments of each of the 56 resistant and wild-type viral populations. D) PCR reactions 
expanding 58.5 °C selected viral populations. 
 
3.5 Observed mutations in thermostable viral populations 
3.5.1 Synonymous and non-synonymous mutations 
The results of sequencing the putative thermostable populations identified a number of 
mutations which were present in thermostable mutants but absent in the reference and 
sequenced SVV-001. These include synonymous and non-synonymous mutations. Figure 16 
below lists the mutations within the sequenced DNA, these were present in both the 56 °C 
resistant and 58.5 °C selected viral populations, and their relative conservation across 96 




















Figure 16: Mutations observed in the thermostable SVV mutants. Four mutations were 
identified in the sequenced portion of the mutant genomes, A1776G, C2526T, A3434G and 
G3777A. These were organised by effect on translated polyprotein and degree to which they 
are present in 96 sequenced Senecavirus isolates available in Genbank. 
 
Among the four mutations in the sequenced region of the 56°C resistant and 58.5 °C selected 
viral populations there were two synonymous mutations, which were well conserved in 96 of 
the Senecavirus isolate full genomes accessible through Genbank. Conversely, the two non-
synonymous mutations were not seen in any of the other 96 Senecavirus isolates. 
 
3.5.2 Structural protein mutations 
To gain insight into how the VP2 I206V mutation may affect thermostability, the SVV-001 
protomer was modelled using UCSF Chimera. Using in-built tools, interactions between 
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below provides a representation of the position of VP2 I206V mutation within the SVV-001 

















Figure 17: VP2 I206V is predicted to decrease intraprotomeric binding. A) The SVV-001 
capsid protomer with area of interest highlighted was visualised using UCSF Chimera 
(accession number 3CJI). B) The highlighted area of A) showing the interactions (highlighted 
with yellow lines) between VP2 H204 and residues including VP2 I206 in the wild-type capsid 
as predicted by UCSF Chimera. C) The same highlighted area as in B) with the same 
parameters for internal binding applied but with the VP2 I206V residue shown in dark red. D) 
The results of mCSM, SDM, and DUET predictions of the change of stability as a result of the 
introduction of the I206V mutation. 
 
3.5.3 Genomic RNA secondary structural mutations 
To predict the effect of synonymous and non-synonymous mutations on the secondary structure 
of the SVV viral genome, the wild type and mutant sequences were entered into the RNAfold 
WebServer and the predicted structures shown below in Figure 18. The A1776G, C2526U and 





noticeable degree. The A3434G mutation is not predicted to alter the secondary structure of 




Figure 18: Predicted secondary structures of wild type and mutant genomic RNA. A) The 
thermostable mutant genome structure as predicted by RNAfold WebServer. B) The SVV-001 
genome structure as predicted by the RNAfold WebServer. In A) and B), areas of interest of 
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3.6 SDS-PAGE analysis 
3.6.1 SDS PAGE analysis of wild type and mutant SVV structural proteins 
As the VP2 I206V mutation is predicted to ablate interaction with H204, the residue essential 
for the cleavage of VP0 to VP2 and VP4, it was hypothesised that this would manifest in a 
difference in the proportion of precursor and cleaved structural proteins present in the wild-
type vs. mutant virus. To investigate whether this was the case, protein from wild-type and 


















WT 56 ℃ 58.5 ℃B
24
 76 
Figure 19: Protein bands observed in SVV-001 lane appear different to those in the 56 °C 
resistant and 58.5 °C selected viral mutants’ lanes. A) As well as appearing better defined 
than the wild-type bands, the mutant lanes also had two strong bands at around 62 kDa and 130 
kDa. B) A later SDS-PAGE gel using wild-type SVV-001 purified by Optiprep® gradient also 
showed bands at around 62 kDa and 130 kDa, note that the 56 resistant and 58.5 selected mutant 
lanes were not considered in further analysis. C) A repeated gel where the wild-type lane was 
not used in further analysis 
 
3.6.2 In silico analysis of SDS-PAGE gels  
ImageJ: Fiji (Schindlen et. al., 2012) was used to quantify the relative intensities of the bands 
corresponding to structural proteins in the SDS-PAGE gels (see: Figure 19). The relative 
intensities of VP2 and VP4 with respect to the precursor VP0 for the wild-type, 56 °C resistant 
and 58.5 selected mutants were measured, with results as shown below in Figure 20. 
 
Figure 20: Wild-type SVV-001 has a greater ratio of VP2 and VP4 with respect to VP0 
than the thermostable mutants. Ratios of ImageJ Fiji analysed structural protein bands from 









Ratios of capsid proteins
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56 °C resistant mutant 
58.5°C selected mutant
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3.7 Mass Spectrometry 
3.7.1 MASCOT database search results of analysed protein bands 
The results of the SDS-PAGE gel raised a number of questions, for instance, the nature of the 
two strong bands that were not present in the wild-type, but that were present in the mutant 
lanes. To determine what exactly these are, they were excised from the gel and submitted to 
Otago’s Centre for Protein Research (CPR). Figure 21 indicates those bands that were 
submitted to CPR, as well as the results of database searches following Matrix-Assisted Laser 
Desorption Ionisation-Time of Flight (MALDI-TOF) mass spectrometry. 
  
Figure 21: Four bands of interest from an SDS-PAGE gel were investigated with mass 
spectrometry. Bands submitted for MALDI-TOF mass spectrometry are denoted “B” (for 
“band”) 1 through 4 and results with respect to database searches are displayed.  
 
Mass spectrometry revealed that the 62 kDa and 130 kDa bands in the initial SDS-PAGE 
experiment were most likely bovine serum proteins. Taken in light of later SDS-PAGE gels, 
these were most likely the result of Optiprep® gradient co-purification. As an internal control, 
the band “B2” was determined, as predicted, to be VP2 of SVV. 
Sample: B1 
Database: SwissProt tryptic search 
Protein hits: ALBU BOVIN Serum 
albumin OS=Bos Taurus OX=9913 
GN=ALB PE=1 SV=4 
 
Sample: B2 
Database: SwissProt tryptic search 
Protein hits: 3CJI C Chain C, 
Structure of Seneca Valley Virus-001 
 
Sample: B3 
Database: SwissProt tryptic search 
Protein hits: ALBU BOVIN Serum 
albumin OS=Bos Taurus OX=9913 
GN=ALB PE=1 SV=4 
 
Sample: B4 
Database: SwissProt tryptic search 
Protein hits: A2MG BOVIN Alpha-2-
macroglobulin OS=Bos Taurus 





3.8 Particle Stability Thermal Release assay (PaSTRy) 
To directly contrast the thermal stability SVV-001 and 56 °C resistant viral populations, 
Particle Stability Thermal Release assays (PaSTRy) were performed with CsCl purified viral 
fractions. Figure 22 below demonstrates capsid destruction as a result of incubation at high 
temperature, using concentration of free RNA and exposure of protein hydrophobic residues 





Figure 22: PaSTRy comparing wild-type SVV-001 with thermostable mutant. Release of 
viral RNA and exposure of hydrophobic residues from capsids in response to heating was 
monitored by SYTO9 and SYPRO Orange dyes respectively, with wild-type shown in dark 
blue, and 56 °C resistant viral population shown in red. In the RNA experiments, thermostable 
virus was assayed three times with triplicate values, and wild-type virus was assayed three 
times as internal controls. The protein experiments were performed with duplicate values. A) 





Results from the RNA-based PaSTRy assays showed an approximate positive 2 °C shift in the 
point of maximal fluorescence between the wild-type (59 °C) and thermostable mutants (61 
°C), confirming the thermostable phenotype of the 56 °C resistant viral population. In the 
hydrophobic residue-based PaSTRy assays, there was a similar difference between the first 
peaks of the wild-type (61 °C) and thermostable virus (63.5 °C), while the secondary peaks 
were near-identical at approximately 84.5 °C. The first peaks correspond to the dissociation of 
virus from full capsids to pentamers, and the secondary peaks correspond to the denaturation 
of pentamers.  
 
3.9 Cryo-electron microscopy 
The 56 °C resistant mutant virus was prepared for cryo-electron microscopy, and a low-
resolution structure was derived using the equipment readily available to Otago Micro and 
Nano Imaging (OMNI), including a JEOL 2200FS and RELION 3.0 software (Scheres, S. H., 
2018). Note that this work was only made possible with assistance from Nadishka 
Jayawardena, who provided supervision and technical support with the JEOL 2200FS 
microscope, as well as invaluable assistance with single particle analysis. 
 
3.9.1 Image collection 
C-flat grids were visualised at 200 kV using a JEOL 2200FS cryo-electron microscope. First, 
grid areas to be examined were chosen based on ice quality. Montages were taken of chosen 
grid areas using in-built software tool Serial EM. From these montages, grid holes were 
labelled and images were acquired of the grid holes and particles therein.  Figure 23 provides 
insight into this process. 
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Figure 23: Cryo-electron microscopy micrograph acquisition. A) A completed montage of 
a grid area with red crosses indicating those grid holes to be imaged B) Image of a grid hole 
with both full and empty capsids visible. 
 
3.9.2 Single particle analysis 
Single particle analysis describes a process by which three-dimensional structures are derived 
from the data collected during cryo-electron microscopy. First image stacks are aligned to 
correct for motion during the exposure of the sample to the electron beam. Particles of interest 
in aligned images were manually picked. Particles that were picked were CTF corrected (see: 
2.16.3 Single particle analysis) and 2D classes were generated to filter out broken and/or junk 
particles and ensure only intact, full viral capsids were to be analysed. Once the 2D classes 
were determined to be of sufficient quality, an initial 3D class was generated using SVV cryo-
EM map as a reference and by imposing icosahedral symmetry (I4). Figure 24 below 






    
Figure 24: Single particle analysis of the 56 °C resistant mutant. A) Examples of particles 
picked from micrographs collected using the JEOL 2200FS electron microscope. B) CTF 
correction of motion corrected micrographs with simulated power spectrum (grey) and 
experimental power spectrum (black). C) 2D classes generated from picked particles including 
intact, broken and/or junk particles. D) 3D reconstruction produced a 10.36 Å resolution 
structure according to the gold standard fourier shell correlation cut-off of 0.143.  
 
3.9.3 Cryo-electron microscopy derived structure of the 56 °C resistant mutant 
Single particle analysis of collected micrographs culminated in a 10.36 Å structure of the 56 































001. This structure was derived from 404 out of 412 initially selected particles.                 
 
Figure 25: Cryo-EM determined structure of the 56°C resistant mutant. Structures of the 
56 °C resistant mutant (A) at 10.36 Å resolution and of SVV-001 at 3.8 Å resolution (B) are 





4.1 Thermostability of wild-type SVV-001 
While there are a variety of means to select for viral mutants with increased stability, for 
example exposure to extreme pH, the application of heat for this purpose was chosen for this 
work as it has a precedence in the literature (Adeyemi et. al., 2017). Successful SVV infection 
of susceptible cells requires binding to ANTXR1, more specifically the binding of the BC loop 
& loop II of VP1, the “puff” of VP2 and the “knob” of VP3, to ANTXR1 (Jayawardena et. al., 
2018). Heat denatures the bonds between the viral proteins that comprise the viral capsid, 
thereby altering the delicate steric relationship of viral proteins and allowing the RNA genome 
to leak out of the capsid and in turn preventing successful infection. With heat selected as the 
means to derive stable mutants, the thermal probe experiments were performed for two reasons. 
Firstly, this was to characterise the thermostability of the SVV-001 viral capsid to provide a 
reference to which any mutant could be compared. Secondly, this was to inform an appropriate 
temperature to be used in a regimen of heating and passage to select for thermostable mutants. 
The first method that was used to determine this was taking aliquots of an SVV-001 stock of 
known viral titre, and measuring the viral titre after exposure to heating for 30 minutes. The 
initial experiments performed showed no appreciable loss in viral titre after incubation for 30 
minutes between 40 °C and 55 °C, with a sharp decrease between 55 °C and 60 °C. After 
heating at 58.5 °C, there was an approximately 99% decrease in viral titre, and so this 
temperature was deemed appropriate for thermal selection going ahead. In light of the results 
of the thermal selection, which will be discussed later, there was a need to return to the thermal 
probe experiments. The method was therefore changed from comparing heated virus to the titre 
of a known stock, to include paired, equal aliquots of unheated and heated virus of a more 
dilute solution. This indicated that heating at 53.5 °C for 30 minutes causes a statistically 
significant approximately 99% decrease in SVV-001 viral titre. It is not immediately clear for 
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what reason the results from the two sets of experiments were so different. It could be that in 
first method the higher concentration of virus in sample would aggregate, thereby shielding 
some virus from complete exposure to heat. 
 
4.2 Selection for thermostable SVV-001 mutants 
The idea of the thermal selection experiments was to change the fundamental representation of 
SVV-001 virions with thermostable capsids from a minority to a majority, while still preserving 
qualities important for oncolytic activity, such as the ability to productively infect susceptible 
cells. The first thermal selection experiment, wherein wild-type SVV-001 was exposed to 
heating at 58.5 °C for 30 minutes, produced drastically different results than expected. Rather 
than losing approximately 99%, as the first thermal probe experiment would suggest, the SVV 
viral titre would fall over 99.99% and 99.999%, falling below the limit of detection. When the 
limit was sufficiently changed, there was a measurable 6 log decrease in viral titre down to the 
observation of a single viral plaque post-heating. Though the initial idea was not to plaque-
purify putative thermostable mutants, this single plaque was the only one to come from the 
undiluted sample of the heated viral solution, and was therefore thought to represent a 
maximally and uniquely thermostable population. The single viral plaque was isolated from 
the plaque formation assay and was grown in a confluent T25 culture vessel of H446 cells. The 
concentrated cell lysate from this culture vessel was the “passage zero” for the forthcoming 56 
°C and 58.5 °C thermal selection experiments. The difference between the expected results 
from the thermal probe and the observed results from the first thermal selection experiment 
was the basis for the revision of the method of the thermal probe. An important but minor 
finding from this experiment was that infection of susceptible cells with a known MOI of SVV-
001 reliably produced similar titres of progeny virus.  
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As the single viral plaque was originally isolated from a wild-type SVV population heated to 
58.5 °C, it was pertinent to determine whether this population was completely resistant to 
heating at this temperature. As it would turn out, it was not, and repeated passage and heating 
over 10 successive passages was not sufficient to select for a population that was completely 
resistant to heating at 58.5 °C. This finding was not entirely unexpected however, as literature 
on related viruses provides insight as to why this may be. In poliovirus, thermostable virus 
could be selected for that would be completely resistant to heating at 53 °C for 30 minutes, but 
a population that was completely resistant to heating at 57 °C for 30 minutes could not be 
selected for (Adeyemi et. al., 2017). This is consistent with findings in foot-and-mouth disease 
virus (FMDV) that capsid instability, as determined in the case of FMDV by mutually repellent 
charged residues on the interpentameric axis, is a property necessary for preserving infectivity 
(Lopez-Agruello et. al., 2019). Both of those studies suggest the pursuit of selection for 
thermostable mutants with conserved infectivity is inherently a self-limiting process.  
 
While there was no discernible trend of adaptation of the plaque purified viral population to 
heating at 58.5 °C, the amount of viral titre produced after every passage gradually decreased 
over the course of the experiment. This is despite infection at a constant MOI. It was reasoned 
that the virus that has been through 10 successive passages may have developed additional, or 
alternative, mutations conferring thermostability, as was the case in poliovirus after 10 
successive passages at 57 °C (Adeyemi et. al., 2017).  For these reasons it would be purified 
and the capsid coding region sequenced. 
 
As the plaque purified viral population was similarly resistant to heating at 58.5 °C as the wild-
type SVV-001 was to heating at 53.5 °C, it was reasonable to expect that the plaque purified 
population would be resistant to heating at a temperature less than 58.5 °C but higher than 53.5 
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°C. The plaque purified viral population was evaluated for resistance to 56 °C, the average of 
the two values, and was shown to be completely resistant to heating at this temperature across 
three successive passages. The virus from the final passage of each of the 58.5 °C and 56 °C 
thermal selection experiments were used in forthcoming purification and sequencing 
experiments.  
 
Though the thermostable phenotype of the mutant virus could be inferred from the results of 
the plaque formation assays, it is important to remember that plaque formations assays are, by 
nature, based on infectivity. SVV infectivity is based in large part on receptor binding, a 
property which would necessarily be conserved in any thermostable mutants from which VLPs 
are to be derived. For this reason, plaque assays are valuable in selecting for thermostable virus 
with conserved functionality. Conversely, plaque assays comparing the heated and unheated 
populations do not strictly measure the effect of heating on capsid integrity, rather they measure 
the effect of heating on infectivity. This is where PaSTRy becomes advantageous. PaSTRy 
utilises fluorescent dyes to monitor the levels of indicators of molecule denaturation in 
response to heat, such as exposure of protein hydrophobic residues, or levels of free RNA 
accessible to the dye. As PaSTRy does not rely on successful infection and lysis of prey cells, 
comparison between the wild-type and thermostable mutant response to heating using PaSTRy 
is a direct comparison of capsid stability. The results of the PaSTRy experiments showed an 
approximate 2 °C difference between in the fluorescence associated with capsid degradation 
of the wild-type and thermostable mutants, as measured by release of free RNA and exposure 
of hydrophobic residues. For the RNA measurements, the wild-type showed maximal 
fluorescence at approximately 59 °C and the 56 °C resistant mutant displayed maximal 
fluorescence at 61 °C. The protein results were somewhat different, with the wild-type 
plateauing after 61 °C and the 56 °C resistant mutant plateauing after heating to 63.5 °C. This 
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would suggest that RNA release precedes exposure of hydrophobic residues. This would be 
consistent with the RNA evacuating the capsid before dye can penetrate and bind the 
hydrophobic residues on the inside of the capsids. This may also speak to why rather than 
discreet peaks as seen in the RNA PaSTRy experiments, the increase in fluorescence in the 
protein PaSTRy has a much flatter curve. Whereas the RNA release conceivably occurs 
rapidly, due to the pressure difference across the capsid, hydrophobic residues may be 
continually exposed as the heat denatures viral capsids. The difference between the two viral 
populations as measured by PaSTRy would appear slight, especially when compared to plaque 
assay results, highlighting the importance of using both. 
 
Aside from the RNA fluorescence peaks at around 59 °C and 61 °C for the wild-type and 
mutant respectively, there were smaller, secondary peaks were seen at higher temperatures. 
These smaller peaks were at approximately 84 °C  for the thermostable mutant and 85 °C for 
the wild-type. Similar results were observed in another picornavirus, Equine Rhinitis A virus 
(ERAV), using another RNA-binding dye, SYBRgreen2 (Walter et. al., 2012). In the case of 
ERAV, smaller peaks were seen around 81 °C. The exact nature of these smaller peaks was not 
commented on (Walter et. al., 2012). Due to the extreme nature of the temperatures at which 
the secondary peaks are observed, it is unlikely that they represent capsid degradation of a viral 
sub-population. Most likely, the secondary peaks represent the denaturation of RNA secondary 
structures, which would free up additional nucleotide lengths for dye-binding. If the secondary 
structures of the genome have indeed changed between the wild-type and thermostable SVV, 




4.3 Altered capsid maturation as the likely modality granting thermostability to mutant 
SVV-001 
The explicit intent of this project was to determine mutations conferring stability to the SVV 
capsid, for the production of Virus-Like Particles. This means that the mutations that are of the 
greatest interest to this project are non-synonymous mutations in the SVV structural proteins. 
Investigations into both thermally selected mutants only found one such mutation, VP2 I206V. 
It was not immediately obvious how, if at all, this mutation may confer thermostability to the 
SVV viral capsid. Commonly, mutations conferring thermostability to picornaviral capsids 
increase the internal binding of these capsids, either within protomers (Adeyemi et. al., 2017) 
or between pentamers (Lopez-Arguello et. al., 2019). This appears not to be the case with VP2 
I206V, as modelling with DUET software indicated that the mutation itself is decreases the 
overall internal binding of the SVV protomer. VP2 I206V is not positioned at either the inter-
protomeric or interpentameric interfaces, and so most likely does not act to strengthen binding 
between capsid subunits. Further in silico analysis of the VP2 I206V mutation with UCSF 
Chimera predicted that the substitution of isoleucine with the shorter valine is predicted to 
ablate interaction with VP2 H204. VP2 H204 is an amino-acid previously identified as being 
integral to the cleavage of VP0 to VP2 and VP4 in SVV, with homologues in other 
picornaviruses, including VP2 H195 in PV and VP2 H145 in FMDV (Strauss et. al., 2018). If 
the interaction with VP2 I206 is important for the positioning and/or function of VP2 H204, 
then this would manifest as a change in the relative proportions of VP0 to VP2 and VP4 
observed between the wild-type and mutants. For this reason, we isolated the structural proteins 
from wild-type and mutant SVV and analysed these with SDS-PAGE gel electrophoresis. The 
bands seen in the mutant and wild-type lanes were quite different, with strong, distinct bands 
at approximately 62 kDa and 130 kDa in the mutant lane that were not present in the wild-type 
lane. As these seemed to be rough multiples of the 36 kDa VP2 protein, or fusions of multiple 
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capsid proteins, we hypothesised that perhaps there may have been altered capsid protein 
translation in the thermostable mutants. These would be investigated with mass spectrometry. 
For mass spectrometry, bands of interest were extracted from SDS-PAGE gels and submitted 
to Otago’s Centre for Protein Research, where analysis and database referencing revealed that 
the approximately 62 and 138 kDa bands were bovine serum proteins. These were most likely 
co-purified with SVV during optiprep gradient purification. As in the original SDS-PAGE gel 
the wild-type SVV-001 was purified with caesium chloride gradient, this would likely explain 
why those bovine serums were not present in the wild-type. Repeated gels with wild-type SVV-
001 likewise purified by Optiprep® gradient revealed similar higher kDa bands to those seen 
in the thermostable mutant lanes, precluding the conclusion that these bands were in some way 
related to the thermostable phenotype of the mutants. Though identical protein amounts were 
loaded in the initial SDS-PAGE experiment, the presence of bovine serum proteins in the 
Optiprep® purified samples would have contributed to the measured protein concentration, 
and thus direct comparison of the band intensities of the structural proteins of the wild-type 
and thermostable virus would have been inappropriate. For this reason, the band intensities for 
structural proteins were compared to each other within their own lanes. The initial gel that was 
run suggested that the ratio of VP2 and VP4 when compared to VP0 was non-significantly 
lower in the thermostable mutants than in the wild-type. This supports the idea the VP2 I206V 
mutation impacts the cleavage of precursor structural proteins. Work from within this lab has 
shown that as well as the genome packaged capsid, the SVV procapsid has cleaved VP0 
(Strauss et. al., 2018). This means that whatever degree of thermostability that VP2 I206V 
confers, any SVV VLP’s produced also stand to benefit from. It is worth mentioning as well 
that the A1776G mutation is predicted to alter the secondary structure of the SVV-001 genome, 
and as the RNA genome interacts with the interior of the capsid, this may play a role in 
improving the thermostability of the mutant virion (Shakeel et. al., 2016). 
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While technically in the structural proteins coding sequences, the C2526U and A3434G 
mutations are synonymous mutations, and so do not alter the translated structural proteins. This 
does not necessarily mean that they do not have any impact on thermostability. As previously 
mentioned, the RNA bound within picornaviral capsids can interact with the interior of the 
capsid structural proteins (Shakeel et. al., 2016). The C2526U mutation is predicted to change 
the secondary structure of the RNA genome, which may alter the interactions between the 
genome and the capsid interior. The A3434G mutation however, is not predicted to appreciably 
change the secondary structure of the viral genome, and so may simply be a chance mutation, 
that does not contribute to the thermostable phenotype. 
 
Finally, the G3777A mutation is an interesting one, as it is outside the capsid-encoding P1 
region of SVV-001 and therefore cannot have an impact on the capsid protein stability. It is 
located in the sequence encoding the viral 2B protein, which in most picornaviruses is a 
viroporin. Viroporins are relatively small proteins which oligomerise and permeabilise lipid 
membranes (Nieva et. al., 2012). Picornaviral 2B proteins localise to the endoplasmic reticulum 
and Golgi complex, where mulitmers form pores through which small solutes can leak out 
(Nieva et. al. 2003). This raises questions as to how, if at all, the G3777A mutation might 
contribute to the replication of the thermostable selected mutants. Hypothesis generation is 
further complicated by the low degree of primary sequence identity between picornaviral 2B 
proteins, as shown by the initial study reporting the discovery of SVV-001, where no 
picornaviral species shared an excess of 20% sequence identity with SVV-001 (Hales et. al., 
2008). Despite low sequence identity, picornaviral 2B proteins are thought to have a high 
degree of structural similarity with each other, sharing a helix-turn-helix motif that is 
responsible for the membrane binding activity. G3777A is predicted to have an effect on the 
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secondary structure of the RNA genome, which presents a much clearer way in which it might 
contribute to the thermostable phenotype. 
 
Cryo-electron microscopy was undertaken to discern any changes to the structure of the 
thermostable mutant virus as a result of mutations in the structural proteins and/or RNA 
genome. From CsCl purified fractions, a 10.36 Å structure was derived of the 56 °C resistant 
mutant. Unfortunately, as 10.36 Å is relatively low resolution, the conclusions that can be 
drawn from this structure are limited. At this resolution, it would appear that the thermostable 
mutant is not appreciably different to a 3.8 Å structure of the SVV-001 capsid. 
 
4.4 Summary 
This work sought to determine residues and mutations thereof that confer thermal stability to 
the SVV-001 capsid, to inform the production of thermostable VLPs. First, the temperature 
sufficient to exert a significant selection pressure on SVV-001 was investigated. Early results 
from this investigation lead to the heating of SVV-001 to 58.5 °C for 30 minutes, which when 
enumerated produced a single viral plaque. This single viral plaque was extracted and grown 
in H446 cells while the method for determining an appropriate selection temperature was 
amended. With the amended method, roughly 99% of wild-type SVV-001 was shown to be 
inactivated as a consequence of heating at 53.5 °C for 30 minutes. When tested similarly, the 
plaque purified viral population was completely resistant to heating at 56 °C for 30 minutes, 
and could not be successfully be selected to be fully resistant to heating at 58.5 °C after 30 
minutes. Wild-type SVV-001, as well as viral populations that were resistant to heating at 56 
°C, and that had undergone 10 successive passages with heating at 58.5 °C, were then 
expanded, purified and sequenced. This revealed a number of mutations inside and outside of 
the capsid coding region of the genome which were present in the 56 °C resistant and 58.5 °C 
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selected viral populations that were not present in wild-type SVV-001. These mutations were 
then modelled in silico. One mutation in particular, VP2 I206V, was reasoned to alter the 
relative amounts of the capsid proteins VP2 and VP4 versus their precursor VP0. Protein from 
purified viral fractions was precipitated out and analysed using SDS-PAGE. This suggested 
that there was a non-significantly increased proportion of VP0 in the thermostable mutants than 
in the wild-type SVV-001. The SDS-PAGE results also showed two bands in the thermostable 
mutant lanes at approximately 62 kDa and 130 kDa, which were confirmed by mass-
spectrometry to be bovine serum proteins. Repeated SDS-PAGE with SVV-001 purified by 
Optiprep® gradient also showed two similar bands. The wild-type and 56 °C resistant viral 
populations were then directly contrasted with PaSTRy. PaSTRy demonstrated that the capsids 
of wild-type virus dissociate and release RNA from around 59 °C, whereas capsids of 56 °C 
resistant virus dissociate do the same from 61 °C onwards. Finally, CsCl purified 56 °C 




5 Future Work 
This work identified mutations present in thermally selected populations of the novel oncolytic 
virus, Seneca Valley Virus. Though four mutations were initially identified, it would seem that 
only one of these would likely be of utility of the production of thermostable VLPs, as was the 
express purpose of undertaking this project. This was the VP2 I206V mutation. Naturally, 
future work would involve the introduction of the VP2 I206V mutation in to the wild-type 
SVV-001 and the verification of the presence or absence of the thermostable phenotype. 
 
Continuing on the assumption that VP2 I206V is experimentally demonstrated to confer 
increased structural stability to the SVV-001 capsid, the next objective would be to determine 
if the VP2 I206V mutation would similarly increase the structural stability of the empty capsid 
of SVV-001 compared to the wild-type empty capsid. As the VLP is non-infectious, VLP titres 
post-heating would have to be measured using a different method than the plaque assays used 
for determining SVV viral titres. Looking further in to the development of stable VLP’s, 
strategies would have to be developed for the successful packaging of cytotoxic drugs into the 
SVV-001 VLP. As in FMDV there has been putative packaging signals identified within the 
secondary structures of the genome (Logan et. al., 2018), it stands to reason SVV may have 
similar packaging signals. At the time of this writing, this lab is undertaking work to determine 
the presence of packaging signals within the SVV genome. If they are discovered, they will 
present a likely route by which cytotoxic drugs can be introduced into the SVV VLP. 
 
This project also resulted in solving the structure of the 56 °C resistant SVV to a resolution of 
10.36 Å. Further work would entail solving the structure to a much higher resolution so as to 
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7 Supplementary Figures 
7.1 Alignments of the thermostable SVV mutants against 96 Senecavirus isolates 





Figure 26: Clustal omega alignment of the A1776G mutation against analogous sites in 
96 Senecavirus A isolates. SVV-001 thermostable mutant sequence is shown on the top row 
(shortened to SVV-001), with the rest annotated with their genbank accession numbers. 
Senecavirus isolates that share the mutation are shown in in green, with those that don’t shown 
in red. The A1776G mutation does not appear in any of the Senecavirus isolates tested. 
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Figure 27: Clustal omega alignment of the C2527U mutation against analogous sites in 
96 Senecavirus A isolates. Senecavirus isolates that share the mutation are shown in in green, 
with those that don’t shown in red. The C2527T mutation is well conserved appearing in 85.4% 
of tested Senecavirus isolates. 
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Figure 28: Clustal omega alignment of the A3434G mutation against analogous sites in 
96 Senecavirus A isolates. Senecavirus isolates that share the mutation are shown in in green, 
with those that don’t shown in red. The A3434G mutation is well conserved appearing in 92.7% 
of tested Senecavirus isolates. 
 117 































Figure 29: Clustal omega alignment of the G3777A mutation against analogous sites in 
96 Senecavirus A isolates. Senecavirus isolates that share the mutation are shown in in green, 
with those that don’t shown in red. The G3777A mutation, like the A1776G mutation, does not 
appear in any other tested Senecavirus isolates. 
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7.2 ImageJ Fiji analysis of SDS PAGE gels  
 
 
Figure 30: ImageJ Fiji analysis of SDS PAGE gels. A, D & G Lanes to be analysed within 
the SDS PAGE gels were defined using in-built tools B, E & H From defined areas, plots were 
generated as functions of intensity versus position within the defined areas C, F & I Area under 
the curves were calculated for peaks manually divided to better represent discreet bands.  
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